Exhibit 31

0001295345-16-000646.txt : 20160822 0001295345-16-000646.hdr.sgml : 20160822 20160822170736 ACCESSION NUMBER: 0001295345-16-000646 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 48 CONFORMED PERIOD OF REPORT: 20160630 FILED AS OF DATE: 20160822 DATE AS OF CHANGE: 20160822 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Emerald Medical Applications Corp. CENTRAL INDEX KEY: 0000797542 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 680080601 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-15746 FILM NUMBER: 161845853 BUSINESS ADDRESS: STREET 1: 7 IMBER STREET CITY: PETACH TIKVA STATE: L3 ZIP: 4951141 BUSINESS PHONE: 97237444505 MAIL ADDRESS: STREET 1: 7 IMBER STREET CITY: PETACH TIKVA STATE: L3 ZIP: 4951141 FORMER COMPANY: FORMER CONFORMED NAME: ZAXIS INTERNATIONAL INC DATE OF NAME CHANGE: 19950916 FORMER COMPANY: FORMER CONFORMED NAME: INFERGENE CO DATE OF NAME CHANGE: 19920703 10-Q 1 mrla06302016.htm FORM 10-Q FOR THE PERIOD ENDED JUNE 30, 2016

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________

FORM 10-Q
___________________

ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2016

Commission file number: 0-15476

EMERALD MEDICAL APPLICATIONS CORP.
(Exact Name Of Registrant As Specified In Its Charter)

Delaware	68-0080601
(State of Incorporation)	(I.R.S. Employer Identification No.)

7 Imber Street, Petach Tivka, Israel	4951141
(Address of Principal Executive Offices)	(ZIP Code)

Registrant's Telephone Number, Including Area Code: +(972) 3-744-4505

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer (as defined in Rule 12b-2 of the Exchange Act) or a smaller reporting company.

Large accelerated filer ¨

Accelerated filer ¨

Non-Accelerated filer ¨

Smaller reporting company x

On August 22, 2016, the Registrant had 19,505,711 shares of common stock outstanding.

TABLE OF CONTENTS

Item	Description

	PART I - FINANCIAL INFORMATION

ITEM 1.	FINANCIAL STATEMENTS	3
ITEM 2.	MANAGEMENT'S DISCUSSION AND ANALYSIS AND RESULTS OF OPERATIONS	17
ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	20
ITEM 4.	CONTROLS AND PROCEDURES	20

	PART II - OTHER INFORMATION

ITEM 1.	LEGAL PROCEEDINGS	20
ITEM 1A.	RISK FACTORS	20
ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	20
ITEM 3.	DEFAULT UPON SENIOR SECURITIES	21
ITEM 4.	MINE SAFETY DISCLOSURE	21
ITEM 5.	OTHER INFORMATION	21
ITEM 6.	EXHIBITS	21

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS Back to Table of Contents

Balance Sheets - June 30, 2016 (Unaudited) and December 31, 2015	3
Statements of Operations - Three and Six Months Ended June 30, 2016 and 2015 (Unaudited)	4
Statements of Comprehensive Income (Loss) - Three and Six Months Ended June 30, 2016 and 2015 (Unaudited)	5
Statements of Cash Flows - Six Months Ended June 30, 2016 and 2015 (Unaudited)	6
Notes to Unaudited Interim Financial Statements	7

Emerald Medical Applications Corp.
Balance Sheets
As of June 30, 2016 (Unaudited) and December 31, 2015
Back to Table of Contents

	June 30, 2016 (Unaudited)		December 31, 2015
Assets
Current assets:
Cash and cash equivalents	$	274,759	$	115,449
Other receivable		8,212		25,797
Total current assets		282,971		141,246

Fixed assets, net
Fixed assets, net of accumulated depreciation of $10,751 and $6,536, respectively		17,735		21,120
Total assets	$	300,706	$	162,366

Liabilities and Stockholders' Equity (Deficit)
Current liabilities:
Accounts payable and accrued liabilities	$	48,204	$	90,705
Employee payable		22,786		25,612
Employee payable - related party		3,081		3,480
Accrued interest payable		21,887		19,285
Short-term notes payable		186,336		119,974
Convertible note payable, default		29,719		-
Convertible note payable, net of discount of $412,628 and $0, respectively		222,377		29,719
Total current liabilities		534,390		288,775
Total liabilities		534,390		288,775

Stockholders' equity (deficit)
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; none issued.		-		-
Common stock, $0.0001 par value; 490,000,000 shares authorized;
19,474,461 and 15,325,889 shares issued and outstanding at June 30, 2016 and December 31, 2015		1,948		1,533
Accumulated other comprehensive income		(24,178)		(19,337)
Additional paid-in capital		11,738,066		8,752,711
Accumulated deficit		(11,949,520)		(8,861,316)
Total stockholders' deficit		(233,684)		(126,409)
Total liabilities and stockholders' equity (deficit)	$	300,706	$	162,366

The accompanying notes are an integral part of these financial statements.

Emerald Medical Applications Corp.

Statements of Operations

For the Three and Six Months Ended June 30, 2016 and 2015

(Unaudited)

Back to Table of Contents



Three months Three months Six months Six months

ended ended ended ended

June 30, 2016 June 30, 2015 June 30, 2016 June 30, 2015



Revenues $ - $ - $ - $ -



Expenses:

   Research and development (192,002) (237,095) (295,350) (247,400)

   General and administrative expenses (969,214) (5,570) (2,768,736) (174,391)

Total operating expenses (1,161,218) (242,665) (3,064,086) (421,791)



Loss from operations (1,161,218) (242,665) (3,064,086) (421,791)



Other income (expense):

   Interest expense (14,128) (4,346) (21,887) (11,829)

   Change in fair value of derivative - - - 367

   Depreciation and amortization expense (47,718) - (51,665) -

   Other income (expenses) 28,587 - 28,587 -

   Gain/(loss) from foreign currency 6,503 (4,110) 20,847 1,808

Financial income (expense) (26,756) (8,456) (24,118) (9,654)



   Provision for income taxes - - - -



Net loss $ (1,187,974) $ (251,121) $ (3,088,204) $ (431,445)



Basic and diluted (net loss per share) $ (0.06) $ (1.18) $ (0.17) $ (2.03)

Weighted average shares outstanding - basic and diluted 18,890,670 213,001 18,121,314 213,001



The accompanying notes are an integral part of these financial statements.

Emerald Medical Applications Corp.

Statements of Comprehensive Income (Loss)

For the Three and Six Months Ended June 30, 2016 and 2015

(Unaudited)

Back to Table of Contents



Three months Three months Six months Six months

ended ended ended ended

June 30, 2016 June 30, 2015 June 30, 2016 June 30, 2015

Net loss $ (1,187,974) $ (251,121) $ (3,088,204) $ (431,445)

Change in unrealized foreign currency translation gain (loss) (3) (15,771) (4,841) (25,550)

   Total comprehensive loss $ (1,187,977) $ (266,892) $ (3,093,045) $ (456,995)



The accompanying notes are an integral part of these financial statements.

Emerald Medical Applications Corp.

Statements of Cash Flows

For the Six Months Ended June 30, 2016 and 2015

(Unaudited)

Back to Table of Contents



Six months Six months

ended ended

June 30, 2016 June 30, 2015

Operating Activities:

Net loss $ (3,088,204) $ (431,445)

Adjustments to reconcile net (loss) to net cash (used in) operating activities:

   Depreciation expense 8,293 1,878

   Amortization of debt discount 43,373 4,399

   Change in fair value of derivative liabilities - (367)

   Shares issued for services 2,074,736 -

   Options issued for services 455,032 -

Increase (decrease) in cash resulting from change in:

   Due from related party - (6,443)

   Decrease (increase) in other receivable 17,585 (25,689)

   (Decrease) increase in accounts payable (1,777) (2,577)

   (Decrease) increase in accounts payable - related party - 1,087

   Employee payable - 23,800

   (Decrease) increase in other current liabilities - 14,202

   (Decrease) increase in accrued expenses (45,779) 7,430

Net cash used in operating activities $ (536,741) $ (413,725)



Investing Activities:

   Cash paid for fixed assets $ (474) $ 25,317

Net cash provided by investing activities $ (474) $ 25,317



Financing Activities:

   Borrowings on debt $ 735,913 $ 531,798

   Principal payments on debt (34,547) -

Net cash provided by financing activities $ 701,366 $ 531,798



   Foreign currency adjustment (4,841) (25,550)



Net increase (decrease) in cash 159,310 67,206

Cash and cash equivalents - beginning of period 115,449 14,411

Cash and cash equivalents - end of period $ 274,759 $ 81,617



Non-cash transactions:

   BCF due to convertible note payable $ 456,000 $ -

   Cashless conversion of class B warrants $ 193 $ -



The accompanying notes are an integral part of these financial statements.

Emerald Medical Applications Corp
Notes to Unaudited Interim Financial Statements
June 30, 2016
Back to Table of Contents

Note 1. The Company

Organizational Background

Emerald Medical Applications Corp. ("the Company") (f/k/a Zaxis International Inc.) was incorporated in Ohio in 1989, it's fiscal year end is December 31st. On August 25, 1995, The Company merged with a subsidiary of The InFerGene Company ("InFerGene") and InFerGene changed its name to The Company International Inc. InFerGene was incorporated in California in 1984 and subsequently changed its domicile in connection with the merger into The Company to Delaware in 1985. Operations ceased operations in 2002. In November 2002, the Company and its subsidiaries filed a petition for bankruptcy in the U.S. Bankruptcy Court Northern District of Ohio. On October 13, 2004, the Company emerged from bankruptcy.

On July 14, 2015 the closing of the Share Exchange Agreement was held (the "Closing") and as a result, Emerald Medical Applications Ltd. became a wholly-owned subsidiary of the Registrant. Pursuant to the Closing of the Share Exchange Agreement, the Company issued 5,474,545 shares of its common stock, par value $0.0001 (the "Shares" or "Common Stock") to Lior Wayn, Emerald's CEO and the sole holder of Emerald Medical Applications Ltd.'s ordinary Shares, representing 40.58% of the company's 13,489,905 outstanding Shares, in exchange for 100% of Emerald Medical Applications Ltd.'s ordinary Shares.

Subsequently to the Closing Mr. Lior Wayn has been appointed as the Company's CEO, and has been granted considerable influence on the appointment of new directors thereby creating a new management structure for the company replacing the old management. Additionally Mr. Wayn is to receive additional shares in the future contingent on the Company achieving commercial milestone. Thus the new management, headed by Mr. Wayn, is considered to be in control of more than 50% of the company and with the ability to make all management decisions.

Emerald is a company organized under the laws of the State of Israel on February 17, 2010. Emerald is digital health Startup Company engaged in the development, sale and service of imaging solutions utilizing its proprietary DermaCompare software that it developed for use in derma imaging and analytics ("DermaCompare"). Emerald believes that its proprietary DermaCompare software represents an advancement in skin cancer screening that should enable physicians to more readily identify and monitor changes in their patients' skin characteristics.

Emerald's DermaCompare solution allows dermatologists and other medical care professionals, using a set of 25 total body photography ("TBP"), to capture sets of skin lesion images with, among other devices, digital cameras, camera-equipped smartphones or tablets. These images are then transmitted online and are remotely analyzed by professionals using our DermaCompare software.

Emerald's sales and marketing plan is to sell licenses for our imaging software to: NHSs, HMOs, health insurance companies, hospitals and medical clinics through distributers, health care channel partners or directly through independent salespersons and/or web purchase to dermatologists and other physicians (GPs) that we expect to purchase licenses based on the number of potential numbers of patients.

Basis of Presentation

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. The Company has not established any source of revenue to cover its operating costs, and as such, has incurred operating losses since inception. Further, as of June 30, 2016, the cash resources of the Company were insufficient to meet its current business plan, and the Company had negative working capital. These and other factors raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

The Company elected December 31 as its fiscal year end.

Significant Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.

Cash and Cash Equivalents

For financial statement presentation purposes, the Company considers those short-term, highly liquid investments with original maturities of three months or less to be cash or cash equivalents. There were no cash equivalents as of June 30, 2016 and December 31, 2015.

Other Receivables

The company treats VAT refunds claimed resulting from excess VAT paid over VAT received as other receivables, amount shown as other receivables as of June 30, 2016 was $8,212.

Currency Translation and other Comprehensive Income

Balance sheet items are translated using all current translation method for self-contained foreign operations (where functional currency = foreign currency) whereby assets and liabilities are translated using the exchange rate on the date of the balance sheet. It translates revenues, expenses, and net income using the average exchange rate during the period. The foreign exchange adjustment that results from applying the all-current method appears in other comprehensive income, a separate shareholders' equity account, and does not affect net income each period.

Property and Equipment

New property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally 5 years. Expenditures for renewals and betterments are capitalized. Expenditures for minor items, repairs and maintenance are charged to operations as incurred. Gain or loss upon sale or retirement due to obsolescence is reflected in the operating results in the period the event takes place.

Valuation of Long-Lived Assets

We review the recoverability of our long-lived assets including equipment, goodwill and other intangible assets, when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on our ability to recover the carrying value of the asset from the expected future pre-tax cash flows (undiscounted and without interest charges) of the related operations. If these cash flows are less than the carrying value of such asset, an impairment loss is recognized for the difference between estimated fair value and carrying value. Our primary measure of fair value is based on discounted cash flows. The measurement of impairment requires management to make estimates of these cash flows related to long-lived assets, as well as other fair value determinations.

Stock Based Compensation

Stock-based awards are accounted for using the fair value method in accordance with ASC 718, Share-Based Payments. Our primary type of share-based compensation consists of stock options. We use the Black-Scholes option pricing model in valuing options. The inputs for the valuation analysis of the options include the market value of the Company's common stock, the estimated volatility of the Company's common stock, the exercise price of the warrants and the risk free interest rate.

Accounting For Obligations And Instruments Potentially To Be Settled In The Company's Own Stock:

We account for obligations and instruments potentially to be settled in the Company's stock in accordance with FASB ASC 815, Accounting for Derivative Financial Instruments. This issue addresses the initial balance sheet classification and measurement of contracts that are indexed to, and potentially settled in, the Company's own stock.

Fair Value Measurements

The Company adopted the FASB standard related to fair value measurement at inception. The standard defines fair value, establishes a framework for measuring fair value and expands disclosure of fair value measurements. The standard applies under other accounting pronouncements that require or permit fair value measurements and, accordingly, does not require any new fair value measurements. The standard clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.

As a basis for considering such assumptions, the standard established a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows.

Level 1. Observable inputs such as quoted prices in active markets;
Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and
Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The Company values its derivative instruments related to embedded conversion features and warrants from the issuance of convertible debentures in accordance with the Level 3 guidelines. For the six-month period ended June 30, 2016 and the twelve month period ending December 31, 2015, the following table reconciles the beginning and ending balances for financial instruments that are recognized at fair value in these consolidated financial statements. The fair value of embedded conversion features that have floating conversion features and tainted common stock equivalents (warrants and convertible debt) are estimated using a Binomial Lattice model. The key inputs to this valuation model as of December 31, 2015, were: Volatility of 143.9% for the six-month period ended June 30, 2016 and 132.4% for the twelve months period ending December 31, 2015, inherent term of instruments equal to the remaining contractual term, quoted closing stock prices on valuation dates, and various settlement scenarios and probability percentages summing to 100%.

Fair Value Measurements at June 30, 2016

Level 3 - Derivative liabilities from:

Balance at
June 30, 2016

New Issuances

Settlements

Change in Fair Value

Convertible Note

Fair Value Measurements at December 31, 2015

Level 3 - Derivative liabilities from:		Balance at December 31, 2015			New Issuances			Extinguishment			Change in Fair Value
Convertible Note		$	-		$	-		$	(20,532)			-

Changes in the unobservable input values would likely cause material changes in the fair value of the Company's Level 3 financial instruments. The significant unobservable input used in the fair value measurement is the estimation for probability percentages assigned to future expected settlement possibilities. A significant increase (decrease) in this distribution of percentages would result in a higher (lower) fair value measurement.

The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of June 30, 2016 and December 31, 2015:

Fair Value Measurements at June 30, 2016

	Level 3
Assets
Total Assets	$	-

Liabilities
Derivative liability	$	-
Total Liabilities	$	-

Fair Value Measurements at December 31, 2015

		Level 3
Assets
Total Assets	$	-

Liabilities
Derivative liability	$	-
Total Liabilities	$	-

The fair values of our debts are deemed to approximate book value, and are considered Level 2 inputs as defined by ASC Topic 820-10-35.

There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the six months ended June 30, 2016 or the year ended December 31, 2015.

The Company had no other assets or liabilities valued at fair value on a recurring or non-recurring basis as of June 30, 2016 or December 31, 2015.

Earnings per Common Share

We compute net income (loss) per share in accordance with ASC 260, Earning per Share. ASC 260 requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. All per share disclosures retroactively reflect shares outstanding or issuable as though the reverse split had occurred January 1, 2012.

Income Taxes

We have adopted FASB ASC 740, Accounting for Income Taxes. Pursuant to ASC 740, we are required to compute tax asset benefits for net operating losses carried forward. The potential benefits of net operating losses have not been recognized in these financial statements because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years.

We must make certain estimates and judgments in determining income tax expense for financial statement purposes. These estimates and judgments occur in the calculation of certain tax assets and liabilities, which arise from differences in the timing of recognition of revenue and expense for tax and financial statement purposes.

Deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax basis of assets and liabilities using the tax rates and laws in effect when the differences are expected to reverse. ASC 740 provides for the recognition of deferred tax assets if realization of such assets is more likely than not to occur. Realization of our net deferred tax assets is dependent upon our generating sufficient taxable income in future years in appropriate tax jurisdictions to realize benefit from the reversal of temporary differences and from net operating loss, or NOL, carryforwards. We have determined it more likely than not that these timing differences will not materialize and have provided a valuation allowance against substantially all of our net deferred tax asset. Management will continue to evaluate the realizability of the deferred tax asset and its related valuation allowance. If our assessment of the deferred tax assets or the corresponding valuation allowance were to change, we would record the related adjustment to income during the period in which we make the determination. Our tax rate may also vary based on our results and the mix of income or loss in domestic and foreign tax jurisdictions in which we operate.

In addition, the calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax regulations. We recognize liabilities for anticipated tax audit issues in the U.S. and other tax jurisdictions based on our estimate of whether, and to the extent to which, additional taxes will be due. If we ultimately determine that payment of these amounts is unnecessary, we will reverse the liability and recognize a tax benefit during the period in which we determine that the liability is no longer necessary. We will record an additional charge in our provision for taxes in the period in which we determine that the recorded tax liability is less than we expect the ultimate assessment to be.

ASC 740 which requires recognition of estimated income taxes payable or refundable on income tax returns for the current period and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized.

Uncertain Tax Positions

When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of FASB ASC 740-10, Accounting for Uncertain Income Tax Positions, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.

Our federal and state income tax returns are open for fiscal years ending on or after December 31, 2011. We are not under examination by any jurisdiction for any tax year. At June 30, 2016 we had no material unrecognized tax benefits and no adjustments to liabilities or operations were required under FIN 48.

Recent Accounting Pronouncements

In September, 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805) ("ASU 2015-16"). Topic 805 requires that an acquirer retrospectively adjust provisional amounts recognized in a business combination, during the measurement period. To simplify the accounting for adjustments made to provisional amounts, the amendments in the Update require that the acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amount is determined. The acquirer is required to also record, in the same period's financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date. In addition an entity is required to present separately on the face of the income statement or disclose in the notes to the financial statements the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date. ASU 2015-16 is effective for fiscal years beginning December 15, 2015. The adoption of ASU 2015-016 is not expected to have a material effect on the Company's consolidated financial statements.

In August, 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date ("ASU 2015-14"). The amendment in this ASU defers the effective date of ASU No. 2014-09 for all entities for one year. Public business entities, certain not-for-profit entities, and certain employee benefit plans should apply the guidance in ASU 2014-09 to annual reporting periods beginning December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 31, 2016, including interim reporting periods with that reporting period.

In April 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2015-03, Interest-Imputation of Interest (Subtopic 835-30) ("ASU 2015-03"), which changes the presentation of debt issuance costs in financial statements. ASU 2015-03 requires an entity to present such costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. Amortization of the costs will continue to be reported as interest expense. It is effective for annual reporting periods beginning after December 15, 2016. Early adoption is permitted. The new guidance will be applied retrospectively to each prior period presented. The Company is currently in the process of evaluating the impact of adoption of ASU 2015-03 on its balance sheets

Going Concern

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. The Company has not established any source of revenue to cover its operating costs, and as such, has incurred an operating loss since inception. Further, as of June 30, 2016, the cash resources of the Company were insufficient to meet its current business plan, and the Company had negative working capital. These and other factors raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

Note 2. Stockholders' Equity.

On January 8, 2015 the shareholders approved a resolution to increase the authorized common shares from 100,000,000 to 490,000,000 shares. All other provisions of the common shares remain unchanged. Also on that date, the Company declared a reverse split of common stock at the ration of 1:4. The stock split was effective January 8, 2015 for holders of record as of that date. Except as otherwise noted, all share, option and warrant numbers have been restated to give retroactive effect to this split. All per share disclosures retroactively reflect shares outstanding or issuable as though the reverse split had occurred at January 1, 2012.

Recent Issuances of Common Stock

Between January 15, 2015 and March 15, 2015, the Company sold a total of 2,052,000 units for cash consideration of $780,000 at a price of $0.40 (the "Units"), each unit comprised of one share of common stock and one Class A warrant exercisable at $0.80 per share with a term 24 month. The relative fair value of the stock with embedded warrants was $351,433 for the common stock and $428,567 for the class A warrants. The warrants were valued using the Black-Scholes model with 153% volatility and discount rates ranging between 0.44% to 0.7%. These units were issued as stock payable and the cash from sale of units was not received for the sale of stock pre-reverse merger.

Between April 1, 2015 and June 29, 2015, the Company sold a total of 1,012,500 units for cash consideration of $405,000 at a price of $0.40 (the "Units"), each unit comprised of one share of common stock and one Class A warrant exercisable at $0.80 per share with a term 24 month. The relative fair value of the stock with embedded warrants was $158,123 for the common stock and $246,877 for the class A warrants. The warrants were valued using the Black-Scholes model with volatility ranging between163% - 177% and discount rates ranging between 0.54% to 0.71%. These units were issued as stock payable and the cash from sale of units was not received for the sale of stock pre-reverse merger.

Between July 1, 2015 and September 30, 2015, the Company sold a total of 140,000 units for cash consideration of $15,000 at price of $0.107 (the "Units"), each unit comprised of one share of common stock and one Class A warrant exercisable at $0.80 per share with a term 24 month. The relative fair value of the stock with embedded warrants was $4,294 for the common stock and $10,706 for the class A warrants. The warrants were valued using the Black-Scholes model with volatility of 153% and discount rates of 0.61%. These units were issued as stock payable and the cash from sale of units was not received for the sale of stock pre-reverse merger.

Between July 1, 2015 and September 30, 2015, the Company sold a total of 862,500 units for cash consideration of $345,000 at price of $0.40 (the "Units"), each unit comprised of one share of common stock and one Class A warrant exercisable at $0.80 per share with a term 24 month. The relative fair value of the stock with embedded warrants was $118,415 for the common stock and $226,585 for the class A warrants. The warrants were valued using the Black-Scholes model with volatility ranging between 153% - 182% and discount rates ranging between 0.54% to 0.71%. Of these units $65,000 were issued as stock payable and the cash from sale of units was not received for the sale of stock pre-reverse merger and $280,000 cash was received subsequent to Closing of the reverse merger.

On July 16, 2015 and August 6, 2015, the company issue 517,900 shares to one service provider and 100,000 shares to two service providers, respectively, for services valued at a total value of $617,900, arrived at using the stock price on date of grant of $1.00 per Nasdaq.com.

On July 16, 2015, 5 Emerald debt holders in amount of $87,910 converted their debt into 274,719 units at a conversion price of $0.32 per unit, each unit comprised of one share of common stock and one Class A warrant exercisable at $0.80 per share with a term 24 month. The Loss on Settlement of Debt recorded was $678,027.

On July 14, 2015 the Company issued Emerald's CEO and founder, Lior Wayn, 5,474,545 shares as per the share purchase agreement valued at $877,380, valued on the date of grant for the price of common stock.

On July 16, 2015 consultants were issued 2,500,000 Class B Warrants exercisable for a two-year period to acquire one (1) share of Common Stock at a price of $0.40 per share; The fair value of these warrants is $2,199,507. The warrants were valued using the Black-Scholes model with volatility of 182% and discount rate of 0.67%. The Class B warrants are fully vested and were accordingly included in expenses as stock based compensation.

On July 16, 2015 consultants were issued 2,536,247 Class C Warrants exercisable for a 90 day period, commencing 90 days after the effective date of this Registration Statement, at an exercise price of $0.40 to acquire one (1) share of Common Stock and one (1) Class A Warrant at an exercise price of $0.80. The fair value of these warrants is $3,143,581. The warrants were valued using the Black-Scholes model with volatility of 182% and discount rate of 0.67%. The Class C warrants are fully vested and were accordingly included in expenses as stock based compensation.

On November 17, 2015 the Company sold 250,000 units for cash consideration of $100,000 at price of $0.40 (the "Units"), each unit comprised of one share of common stock and one Class A warrant exercisable at $0.80 per share with a term 24 month. The relative fair value of the stock with embedded warrants was $41,304 for the common stock and $58,696 for the class A warrants. The warrants were valued using the Black-Scholes model with volatility ranging between 149% and discount rate of 0.50%. These warrants are fully vested and the fair value and included as stock based compensation on the prior year retained earnings.

Between November 5, 2015 and November 16, 2015 the company issue 268,084 shares to three service provider and for services valued at a total value of $268,084, arrived at using the stock price on date of grant of $1.00 per Nasdaq.com.

On October 1, 2015, the Company granted a total of 534,400 stock options (the "Options") to three company employees. The options vest over 5 quarters and are exercisable at prices ranging from $0.01 to $0.40 per Share. The options were valued using the Black-Scholes model with 149% volatility and 0.67% discount rate for a total value of $528,857. Of this amount, $397,547 was expensed as of December 31, 2015 and $42,394 as of March 31, 2016. An additional $42,394 was expensed during the three-month period ended June 30, 2016.

On January 26, 2016 and March 17, 2016, the Company issued 125,000 shares to one service provider and 50,000 shares to two service providers, respectively, for services valued at a total value of $251,250, arrived at using the stock price on date of grant of $1.75 and $0.65, respectively, per Nasdaq.com.

On February 18, 2016, the Company issued 1,195,000 shares to three acting directors, for services valued at a total value of $1,194,403, arrived at using the stock price on date of grant of $1.00 per Nasdaq.com.

On January 26, 2016, consultants that were previously issued 2,500,000 Class B Warrants exercisable for a two-year period to acquire one (1) share of Common Stock at a price of $0.40 per share, exercised the warrants on a cashless basis resulting in 1,928,572 shares issued with no additional related expense booked.

On February 11 and 18, 2016, the Company granted a total of 403,333 stock options (the "Options") to three company employees. The options vest over periods of between 1 and 8 quarters and are exercisable at prices ranging from $0.01 to $0.40 per Share. The options were valued using the Black-Scholes model with 157% volatility and 0.56% discount rate for a total value of $400,914. Of this amount, $231,920 was expensed during the three-months ended March 31, 2016 and $48,711 during the three-months ended June 30, 2016.

On March 24, 2016, a convertible note payable was issued to GoldMed Ltd. The warrants were valued at a fair value of $56,030. The note included a beneficial conversion feature which resulted in a $75,000 discount recorded as a reduction of debt and an increase to additional paid in capital.

On April 5, 2016, the Company issued 150,000 shares to one service provider for services valued at $105,000 based on the Company's stock price of $0.70 per share on the date of issuance.

On May 10, 2016, the Company issued 41,667 shares to one service provider for services valued at $72,911 based on the Company's stock price of $1.75 per share on the date of issuance.

On May 18, 2016, the Company issued 150,000 shares to one service provider for services valued at $102,000 based on the Company's stock price of $0.68 per share on the date of issuance.

On June 28, 2016, the Company issued 175,000 shares to one service provider for services valued at $122,500 based on the Company's stock price of $0.70 per share on the date of issuance.

On June 30, 2016, the Company issued 333,333 shares to one service provider for services valued at $226,666 based on the Company's stock price of $0.68 per share on the date of issuance.

On June 6, 2016, a convertible note payable was issued to Alpha Capital. The attached warrants were valued at a fair value of $440,000. The note included a beneficial conversion feature which resulted in a $300,000 discount recorded as a reduction of debt and an increase to additional paid in capital.

On April 11, 2016, a convertible note payable was issued to Maz Partner. The attached warrants were valued at a fair value of $80,000. The note included a beneficial conversion feature which resulted in a $46,000 discount recorded as a reduction of debt and an increase to additional paid in capital.

On June 30, 2016, a convertible note payable was issued to Ilan Malka. The attached warrants were valued at a fair value of $40,000. The note included a beneficial conversion feature which resulted in a $35,000 discount recorded as a reduction of debt and an increase to additional paid in capital.

On April 14, 2016, the Company granted a total of 450,000 stock options (the "Options") to one Company director. The options vest over periods of between 1 and 3 quarters and are exercisable at $0.60 per share. The options were valued using the Black-Scholes model with 233% volatility and 0.56% discount rate for a total value of $268,839. The Company expensed $89,613 during the three-months ended June 30, 2016 related to these options.

Note 3. Related Party Transactions

On July 16, 2015 5 Emerald debt holders in amount of $87,910 converted their debt into 274,719 units at a conversion price of $0.32 per unit, each unit comprised of one share of common stock and one Class A warrant exercisable at $0.80 per share with a term 24 month. The Loss on Settlement of Debt recorded was $678,027.

The company's CEO, Lior Wayn was owed $3,310 and $3,480 payable as of June 30, 2016 and December 31, 2015, respectively.

Following Closing of the reverse merger, $490,000 loan from Zaxis International Inc. to Emerald Medical Applications Ltd. was rendered an intercompany loan and as such was written off.

Note 4. Employee Payable.

For the periods ended June 30, 2016 and December 31, 2015 the Company had $25,867 and $25,612, respectively, in employee payable related to the monthly wages payable to the company's employees.

Note 5. Notes Payable.

Convertible Notes Payable

On March 24, 2016, the Company issued a convertible promissory note to GoldMed Ltd. in the amount of $75,000. The Convertible Note is convertible to 187,500 units at $0.40 (the "Units"), each unit comprised of one share of common stock and one Class A warrant exercisable at $0.80 per share with a term 24 months. Since the market price on the date of issuance was higher than the conversion price, a beneficial conversion feature was calculated at $78,750, but only $75,000 was recorded. $20,137 was recorded as amortization expense of for the period ending June 30, 2016, compared to amortization expense of $0 as of December 31, 2015.

On June 20, 2016, a $400,000 convertible note payable and 200,000 warrants exercisable at $0.80 per share with a term of 24 months was issued to Alpha Capital. The note included a beneficial conversion feature which resulted in a $300,000 discount recorded as a reduction of debt and an increase to additional paid in capital. The Company recorded an amortization expense of $8,219 related to this note.

On March 31, 2016, a $80,000 convertible note payable and 200,000 warrants exercisable at $0.80 per share with a term of 24 months was issued to Maz Partner. The note included a beneficial conversion feature which resulted in a $46,000 discount recorded as a reduction of debt and an increase to additional paid in capital. The Company recorded an amortization expense of $11,468 related to this note.

On May 24, 2016, a convertible note payable was issued to Ilan Malka. The note included a beneficial conversion feature which resulted in a $35,000 discount recorded as a reduction of debt and an increase to additional paid in capital. The Company recorded an amortization expense of $3,548 related to this note.

Note 6. Payable - Not Convertible

On July 8, 2014 the company issued a convertible promissory note to Axel Springer Plug & Play Accelerator GmbH (the "Holder"), in the amounts of $29,719. The Convertible Notes are convertible at the lessor of a market based discounted and a fixed rate derived from a fixed market cap. The Holders have the right following the Date of Issuance, and until any time until the convertible Promissory Note is fully paid, to convert any outstanding and unpaid principal portion of the Convertible Promissory Note, and accrued interest, into fully paid and non-assessable shares of Common Stock. Holder was not issued warrants with the Convertible Promissory Note.

As of December 31, 2015 this note is no longer convertible since pursuant to the loan agreement the in the event that prior to December 31,2015 (the "Maturity Date"), the Company shall consummate a financing round led by unaffiliated investors in the amount of at least Euro 200,000, at a Company pre-money valuation on a fully diluted basis of at least Euro 750,000 (a "Qualified Round"), the Holder shall be entitled (but not obligated) to convert the entire loan amount into the most senior class of shares of the Company issued in such Qualified Round, based on a price per share equal to the lower of the price per share reflected by a Company pre-money valuation on a fully diluted basis calculated at the time of conversion equal to Euro 1,500,000; or - price per share which reflects a 20% discount on the lowest price per share issued pursuant to such Qualified Round. If upon the occurrence of such event the note holder elects not to convert upon receiving notice of such event, then the loan becomes non-convertible.

On January 14 and 16, 2015, we issued two promissory notes in the amount of $15,000 each to two different unaffiliated party in consideration for cash transferred to the Company (the "January 2015 Notes"). The January 2015 Notes bears interest at the rate of 1% per annum, are due and payable on January 14 and 16, 2016 and are not convertible to common stock.

One of the notes was repaid in full on March 3, 2015 with interest due waived the by the debtor, and the second note was repaid on April 22, 2015 with interest due waived the by the debtor.

During the second quarter of 2015, an agreement was reached with the holder of $120,979 advance payable note to settle the full amount due for $30,000 and interest due. The settlement with all note holders resulted in $528 loss on debt settlement due to the payment being higher than principal and accrued interest as of that date as well as a charge of $90,979 considered a contribution of capital due to the fact that note holder, IMWT, was a related party.

We concluded that these notes have a stated rate of interest that is different from the rate of interest that is appropriate for this type of debt at the date of the transaction. Accordingly, the company imputed interest at an appropriate rate estimated at 8% as prescribed under FASB ASC 835. The resultant charge of $6,280 for the period ending December 31, 2014 and $4,113 for the period ending March 31, 2015 to interest expense was considered a contribution of capital and was recorded in additional paid in capital.

On November 16, 2014 four individuals loaned amount to company, totaling $87,910 with maturity dates of November 16, 2015 and bearing an interest rate of 8% per annum, these notes were fully converted on July 16, 2015 to Company shares of commons stock and warrants as described in Note 3.

On March 9, 2016 four individuals lent the company a total of $34,547 with maturity dates of November 16, 2015 and bearing an interest rate of 8% per annum. As of June 30, 2016, the loan was fully repaid.

For the periods ended June 30, 2016 and December 31, 2015, the Company has recognized $21,420 and $19,285, respectively, in accrued interest expense related to the stated interest rate on the notes. Interest expense for the periods ended June 30, 2016 and June 30, 2015, respectively, were $21,887 and $11,829, as well as $43,372 and $0 from the amortization of debt discount.

Note 7. Commitments and Contingencies

The Company received research and development grants from the State of Israel according to guidelines and procedures of the Office of the Chief Scientist of the Ministry of Industry and Trade. According to the agreement, the Company is obliged to pay royalties on the sale of products developed with the participation of the Chief Scientist. The royalty rate is 3.5% and the total royalties will not exceed the amount of the grants. As of June 30, 2016, the Company had an outstanding contingent liability to pay royalties in the amount of $186,335, with $15,795 in accrued interest.

Note 8. Derivative Liabilities

On July 8, 2014 the company issued a convertible promissory note to Axel Springer Plug & Play Accelerator GmbH (the "Holder"), in the amounts of $29,719.

The Convertible note is convertible at the lessor of a market based discounted and a fixed rate derived from a fixed market cap. The Holder has the right following the Date of Issuance, and until any time until the convertible Promissory Note is fully paid, to convert any outstanding and unpaid principal portion of the Convertible Promissory Note, and accrued interest, into fully paid and non-assessable shares of Common Stock. The Holder was not issued warrants with the Convertible Promissory Note.

The following shows the changes in the derivative liability measured on a recurring basis for the six months ended June 30, 2016 and year ended December 31, 2015.

	Level 3
Derivative Liability at December 31, 2014	$	20,532
Extinguishment of Derivative Liability		(20,532)
Derivative Liability at December 31, 2015	$	-
Derivative Liability at June 30, 2016	$	-

For the periods ended June 30, 2016 and December 31, 2015 the Company has recognized $0 and $2,013, respectively, in accrued interest expense related to the stated interest rate on the notes. Interest expense for the periods ended June 30, 2016 and December 31, 2015, respectively, were $21,887 and $30,604, of which $0 and $0 is from the amortization of debt discount related to this note The note is no longer considered convertible since the lender elected not to convert, and as such the derivative was written off.

As of December 31, 2015 the company has a $0 derivative liability and a $29,719 convertible note payable, net of discount of $0. As of June 30, 2016, the Company has $0 derivative liability and $222,377 of convertible notes payable, net of discount of $412,628.

In accordance to ASC #815, Accounting for Derivative Instruments and Hedging Activities, we evaluated the holder's non-detachable conversion right provision and liquidated damages clause, contained in the terms governing the Note to determine whether the features qualify as an embedded derivative instruments at issuance. Such non-detachable conversion right provision and liquidated damages clause did not need to be accounted for as derivative financial instruments. Additionally, since the conversion price of the two notes represented the fair market value of the Company's common stock at the time of issuance, no beneficial conversion feature exists. We believe that the Company's shares of common stock is and have been very thinly traded during the last 3 years and that the fair value of the stock price was deemed not to be a fair value. Management decided that because the Company's ability to continue as a going concern was in question and that it has no revenue sources that the conversion price was a better measure of fair market value. Based on that decision, no beneficial conversion feature was reflected in the financial statements and the $20,165 extinguishment of debt was reflected in the current period earnings and $0 extinguishment of debt was reflected in the current period earnings.

Note 9. Other Receivables

As of June 30, 2016 and December 31, 2015 the Company had other receivables of $8,212 and $25,797, respectively, which represent VAT refunds claimed resulting from excess VAT paid over VAT received.

Note 10. Accounts Payable and Accrued Liabilities

As of June 30, 2016 and December 31, 2015, the Company had Accounts payable and accrued liabilities of $48,204 and $90,705, respectively.

Note 11. Subsequent Events

On August 4, 2016, 31,250 shares were issued to one service provider as per the terms of the service agreement.

On July 7, 2016, Emerald entered in a Securities Purchase Agreement and a Registration Rights Agreement with Firstfire Global Opportunities Fund LLC, a New York limited liability company (hereinafter "Firstfire"), pursuant to which the Registrant has issued and sold to Firstfire a secured convertible note bearing interest at 8% per annum in the principal amount of $100,000 with a maturity date on June 19, 2017 (the "Note"). In connection with the Securities Purchase Agreement, the Registrant also granted Firstfire 250,000 Class A and 250,000 Class B Warrants.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS AND RESULTS OF OPERATIONS Back to Table of Contents

Overview

The following plan of operation provides information which management believes is relevant to an assessment and understanding of our results of operations and financial condition. The discussion should be read along with our financial statements and notes thereto. This section includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. Forward-looking statements are often identified by words like believe, expect, estimate, anticipate, intend, project and similar expressions, or words which refer to future events. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our predictions.

Plan of Operations

We are a digital health startup company engaged in the development, sale and service of imaging solutions utilizing our proprietary DermaCompare software that we developed for use in derma imaging and analytics (our "DermaCompare" or "Product"). In our development of the DermaCompare technology, we utilized the knowledge learned from advanced military image processing and data analytics to improve the analysis of medical images for the benefit of patients and the medical community. We believe that our proprietary DermaCompare software represents an advancement in skin cancer screening that should enable physicians to more readily identify and monitor changes in their patients' skin characteristics.

DermaCompare is Emerald's first application of its technology, which we believe represents an advance in the early detection of skin cancer. DermaCompare is based on automated image analytics software using advanced algorithms for alignment, anchoring, identifying and detecting changes in the shapes, colors and sizes of skin lesions, which could potentially become Melanoma. We apply our DermaCompare technology in image capture, correction and intelligent data extraction in the market for derma imaging products.

Our DermaCompare solution allows dermatologists and other medical care professionals, using a set of 25 total body photography ("TBP"), to capture sets of skin lesion images with, among other devices, digital cameras, camera-equipped smart phones or tablets. These images are then transmitted online and are remotely analyzed by professionals using our DermaCompare software.

Our DermaCompare imaging software has 2 main modules:

	●	A SaaS cloud-based Dr. Module that can be launched on any desktop computer connected to the Internet; or
	●	Mobile APP for mass population uses can be installed on smart phones or tablets with iOS or Android operating systems.

Our future plans also contemplate the use of wearable computing and imaging devices such as Google glasses or other comparable devices.

Our sales and marketing plan, which has already commenced, is to sell licenses for our DermaCompare imaging software to: NHSs, HMOs, health insurance companies, hospitals and medical clinics through distributers, health care channel partners or directly through independent salespersons and/or web purchase to dermatologists and other physicians (GPs) that we expect to purchase licenses based on the number of potential numbers of patients.

In furtherance of our business plan, which has resulted in us becoming an operating company, we have entered into a series of agreements with unaffiliated third parties for the distribution of its DermaCompare Technology, as follows:

1. On August 12, 2013, Emerald entered into an exclusive distribution with Derma Italy Sri, organized under the laws of the Italy ("Derma Italy"), pursuant to which Derma Italy was granted exclusive distribution rights in Italy;
2. On December 1, 2013, Emerald entered into a distribution agreement with S. Bokhorst - Creatiekracht, organized under the laws of the Netherlands, pursuant to which S. Bokhorst was granted exclusive distribution in the Netherlands;
3. On February 6, 2014, Emerald entered into a distribution agreement with Medical Edge Pty Ltd, organized under the laws of Australia ("Medical Edge"), pursuant to which Medical Edge was granted exclusive distribution rights in the markets of Australia, New Zealand and Oceania;
4. On January 14, 2015, Emerald entered into a Project Agreement with Realize S.A. and Ubitech, entities engaged in IT related to medical technology in Greece, and MEDISP and MPUoP, academic and research institutes in Greece (collectively, the "Greek Partners"). Emerald and the Greek Partners anticipate imminent grants from the Office of Chief Scientist of the State of Israel and the General Secretariat for Research and Technology of Greece, respectively, the proceeds of which will be used for development of enhanced smartphone applications for diagnosis of early stage Melanoma.

During the six months ended June 30, 2016, we raised $735,913 through the issuance of equity and debt and we may be expected to require up to an additional $1.5 million in capital during the next 12 months to fully implement our business plan and fund our operations.

Results of Operations during the three months ended June 30, 2016 as compared to the three months ended June 30, 2015

We have not generated any revenues during the three months ended June 30, 2016 and 2015.

Our general and administrative expenses increased to $969,216 for the three months ended June 30, 2016 as compared to $5,570 during the same period in the prior year. The significant increase was due to increased expenses relating to our new business activities as well as share-based compensation.

Our research and development expenses increased to $192,002 for the three months ended June 30, 2016 as compared to $237,095 during the same period in the prior year. The decrease was due to more focused research and development expenses related to our DermaCare product.

During the three-month period ended June 30, 2016 and 2015, we incurred a loss from operations of $1,161,218 and $242,665, respectively.

Interest expense increased to $14,128 for the three months ended June 30, 2016 as compared to $4,346 during the same period in the prior year due to increased loans.

Depreciation and amortization expense increased to $47,718 for the three months ended June 30, 2016 as compared to $0 during the same period in the prior year due to expenses related to beneficial conversion features of notes issued during the three months ended June 30, 2016.

We incurred other income of $28,587 during the three-month period ended June 30, 2016 as compared to $0 in the same period in the prior year.

We recorded a gain of $6,503 from currency adjustments during the three months ended June 30, 2016 as compared to a loss of $4,110 in the same period in the prior year.

During the three-month period ended June 30, 2016 and 2015 we incurred $1,187,974 and $251,121 in net loss, respectively.

Results of Operations during the six months ended June 30, 2016 as compared to the six months ended June 30, 2015

We have not generated any revenues during the six months ended June 30, 2016 and 2015.

Our general and administrative expenses increased to $2,768,736 for the six months ended June 30, 2016 as compared to $174,391 during the same period in the prior year. The significant increase was due to increased expenses relating to our new business activities as well as share-based compensation.

Our research and development expenses increased to $295,350 for the six months ended June 30, 2016 as compared to $247,400 during the same period in the prior year. The increase during the six-month period was due to additional research and development expenses related to our DermaCare product.

During the six-month period ended June 30, 2016 and 2015, we incurred a loss from operations of $3,064,086 and $421,791, respectively.

Interest expense increased to $21,887 for the six months ended June 30, 2016 as compared to $11,829 during the same period in the prior year due to increased loans. We recorded $0 and $367 in expense related to a change in fair value of derivative during the six month period ended June 30, 2016 and 2015, respectively.

Depreciation and amortization expense increased to $51,665 for the six months ended June 30, 2016 as compared to $0 during the same period in the prior year due to expenses related to beneficial conversion features of notes issued during the six months ended June 30, 2016.

We incurred other income of $28,587 during the six-month period ended June 30, 2016 as compared to $0 in the same period in the prior year.

We recorded a gain of $20,847 from currency adjustments during the six months ended June 30, 2016 as compared to a gain of $1,808 in the same period in the prior year.

During the six-month period ended June 30, 2016 and 2015 we incurred $3,088,204 and $431,445 in net loss, respectively.

Liquidity and Capital Resources

Our balance sheet as of June 30, 2016 reflects current assets of $282,971 consisting of $274,759 in cash and $8,212 in other receivables. As of December 31, 2015, we had current assets of $141,246 consisting of cash of $115,449 and $25,797 in other receivables. We had fixed assets, net of $17,735, as of June 30, 2016 and $21,120 as of December 31, 2015.

As of June 30, 2016, we had total assets of $300,706 and total assets of $162,366 as of December 31, 2015.

As of June 30, 2016, we had total current liabilities of $534,390 consisting of $48,204 in accounts payable and accrued liabilities, $22,786 in employee payable, $3,081in employee payable to related party, $21,887 accrued interest payable, $216,055 in convertible notes payable and $222,377 in short term notes payable.

As of December 31, 2015, we have had total current liabilities of $288,775 consisting of $90,705 in accounts payable and accrued liabilities, $3,480 in accounts payable to related party, $25,612 employee payable, $19,285 in accrued interest, short-term note payable of $119,974 and $29,719 in convertible note payable.

We had negative working capital of $251,419 as of June 30, 2016 and a negative working capital $147,529 at December 31, 2015. Our total liabilities as of June 30, 2016 were $534,390 as compared to $288,775 at December 31, 2015.

During the period ended June 30, 2016, we had negative cash flow from operations of $536,741, which was the result of a net loss of $3,088,204, a decrease in accounts payable of $1,777 and a decrease in accrued expenses of $45,779 offset by $8,293 in depreciation expense, $43,373 in amortization expense, $2,074,736 in non-cash compensation related to the issuance of services, $455,032 related to options issued for services and $17,585 decrease in other receivables.

During the six months ended June 30, 2016, we acquired assets valued at $474 as compared to disposing assets valued at $25,317 in the same period in the prior year.

During the period ended June 30, 2016, we had cash flow from financing activities of $701,366, which was the result of $735,913 proceeds from borrowings offset by debt payments of $34,547.

During the period ended June 30, 2015, we had negative cash flow from operations of $431,725, which was the result of a net loss of $431,445 offset by depreciation expenses of $1,878, amortization of debt expenses of $4,399, a loss of a change in fair value of derivatives of $367, an amount due from related party of $6,443, an increase in other receivables of $25,689, a decrease in accounts payable of $2,577, an increase in accounts payable from related party of $1,087, employee payable of $23,800, an increase in other current liabilities of $14,202 and an increase in accrued expenses of $7,430.

During the period ended June 30, 2015, we had cash flow from financing activities of $531,798 consisting of debt issuance.

There are no limitations in the Company's certificate of incorporation on the Company's ability to borrow funds or raise funds through the issuance of restricted common stock to effect a business combination. The Company's limited resources and lack of having cash-generating business operations may make it difficult to borrow funds or raise capital. The Company's limitations to borrow funds or raise funds through the issuance of restricted capital stock required to effect or facilitate a business combination may have a material adverse effect on the Company's financial condition and future prospects, including the ability to complete a business combination. To the extent that debt financing ultimately proves to be available, any borrowing will subject us to various risks traditionally associated with indebtedness, including the risks of interest rate fluctuations and insufficiency of cash flow to pay principal and interest, including debt of an acquired business.

The Company has only limited capital. Additional financing is necessary for the Company to continue as a going concern. Our independent auditors have unqualified audit opinion for the period ended December 31, 2015 with an explanatory paragraph on going concern.

In view of these matters, realization of a major portion of the assets in the accompanying balance sheet is dependent upon continued operations of the Company. Management believes that actions presently being taken to obtain additional equity financing will provide the opportunity to continue as a going concern.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Back to Table of Contents

We have not entered into, and do not expect to enter into, financial instruments for trading or hedging purposes.

ITEM 4. CONTROLS AND PROCEDURES Back to Table of Contents

Evaluation of disclosure controls and procedures. As of June 30, 2016, the Company's chief executive officer and chief financial officer conducted an evaluation regarding the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Exchange Act).

Management has assessed the effectiveness of our internal control over financial reporting as of June 30, 2016. Management's assessment was based on criteria set forth in Internal Control - Integrated Framework (1992), issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based upon this assessment, management concluded that, as of June 30, 2016, our internal control over financial reporting was not effective, based upon those criteria, as a result of the identification of the material weaknesses described below.

A material weakness is a deficiency or combination of deficiencies in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis.

Specifically, management identified the following control weaknesses: (i) the Company has not implemented measures that would prevent one individual from overriding the internal control system. (ii) The Company utilizes accounting software that does not prevent erroneous or unauthorized changes to previous reporting periods and/or can be adjusted so as not to provide an adequate audit trail of entries made in the accounting software.

Accordingly, while the Company has identified certain material weaknesses in its system of internal control over financial reporting, it believes that it has taken reasonable steps to ascertain that the financial information contained in this report is in accordance with generally accepted accounting principles. The Company does not believe that this control weakness has resulted in deficient financial reporting because the Chief Financial Officer and Chief Executive Officers are aware of their responsibilities under the SEC's reporting requirements and personally certify the financial reports.

Management has determined that current resources would be appropriately applied elsewhere and when resources permit, they will alleviate material weaknesses through various steps.

Changes in internal controls. During the quarterly period covered by this report, no changes occurred in our internal control over financial reporting that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS Back to Table of Contents

None.

ITEM 1A. RISK FACTORS Back to Table of Contents

See risk factors discussed in Part I, "Item 1. Description of Business, subheading Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2015.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS Back to Table of Contents

During the three-month period ended June 30, 2016, the Company issued the following unregistered equity securities:

On April 5, 2016, the Company issued 150,000 shares to one service provider for services valued at $105,000 based on the Company's stock price of $0.70 per share on the date of issuance.

On May 10, 2016, the Company issued 41,667 shares to one service provider for services valued at $172,911 based on the Company's stock price of $1.75 per share on the date of issuance.

On May 18, 2016, the Company issued 150,000 shares to one service provider for services valued at $102,000 based on the Company's stock price of $0.68 per share on the date of issuance.

On June 28, 2016, the Company issued 175,000 shares to one service provider for services valued at $122,500 based on the Company's stock price of $0.70 per share on the date of issuance.

On June 30, 2016, the Company issued 333,333 shares to one service provider for services valued at $226,666 based on the Company's stock price of $0.68 per share on the date of issuance.

Share based payment transactions were accounted for in accordance with the requirements of ASC 505-50 Equity Based Payments to Non Employees. Paragraph 505-50-30-6 establishes that share-based payment transactions with non-employees shall be measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The Company measured share-based payment transactions at the fair value of the shares issued at date of grant, the Company believes that the value of the shares is more reliably measurable.

The Company believes that the issuances and sale of the restricted shares were exempt from registration pursuant to Section 4(2) of the Act as privately negotiated, isolated, non-recurring transactions not involving any public solicitation. The recipients in each case represented their intention to acquire the securities for investment only and not with a view to the distribution thereof. Appropriate restrictive legends are affixed to the stock certificates issued in such transactions. All recipients of restricted shares either received adequate information about the Company or had access, through employment, relation and/or business relationships with the Company to such information.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES Back to Table of Contents

None.

ITEM 4. MINE SAFETY DISCLOSURE Back to Table of Contents

None.

ITEM 5. OTHER INFORMATION Back to Table of Contents

None.

ITEM 6. EXHIBITS Back to Table of Contents

(a) The following documents are filed as exhibits to this report on Form 10-Q or incorporated by reference herein.

Exhibit No.	Description
31.1	Certification of CEO pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of CFO pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of CEO pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification of CFO pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned.

EMERALD MEDICAL APPLICATIONS CORP.

By: /s/ Lior Wayn
Lior Wayn
Chief Executive Officer
(Principal Executive Officer)
Date: August 22, 2016

By: /s/ David Ben Naim
David Ben Naim
Chief Financial Officer
(Principal Financial and Principal Accounting Officer)
Date: August 22, 2016

Pursuant to the requirements of the Securities Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

By: /s/ Yair Fudim
Yair Fudim
Chairman
Date: August 22, 2016

By: /s/ Lior Wayn
Lior Wayn
Director
Date: August 22, 2016

EX-31 2 exh31_1.htm EXHIBIT 31.1 Exhibit 31
CERTIFICATION

I, Lior Wayn, certify that:

1. I have reviewed this quarterly report of Emerald Medical Applications Corp.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this report;

4. The issuer's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as 4efined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the issuer and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the issuer's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the issuer's internal control over financial reporting that occurred during the issuer's most recent fiscal quarter (the issuer's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the issuer's internal control over financial reporting; and

5. The issuer's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the issuer's auditors and the audit committee of the issuer's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the issuer's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether r not material, that involves management or other employees who have a significant role in the issuer's internal control over financial reporting.

Date: August 22, 2016

/s/ Lior Wayn
CEO

EX-31 3 exh31_2.htm EXHIBIT 31.2 Exhibit 31
CERTIFICATION

I, David Ben Naim, certify that:

1. I have reviewed this quarterly report of Emerald Medical Applications Corp.;

(b) Any fraud, whether r not material, that involves management or other employees who have a significant role in the issuer's internal control over financial reporting.

Date: August 22, 2016

/s/ David Ben Naim
CFO

EX-32 4 exh32_1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Emerald Medical Applications Corp. (the "Company") on Form 10-Q for the period ended June 30, 2016 (the "Report"), as filed with the Securities and Exchange Commission on the date hereof, I, Lior Wayn, CEO of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Lior Wayn

Lior Wayn
CEO
Dated: August 22, 2016

A signed original of this written statement required by Section 906 has been provided to Emerald Medical Applications Corp. and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32 5 exh32_2.htm EXHIBIT 32.2 Exhibit 32

Exhibit 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Emerald Medical Applications Corp. (the "Company") on Form 10-Q for the period ended June 30, 2016 (the "Report"), as filed with the Securities and Exchange Commission on the date hereof, I, David Ben Naim, CFO of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

/s/ David Ben Naim

David Ben Naim
CFO
Dated: August 22, 2016

EX-101.INS 6 mrla-20160630.xml

-192002

-237095

-295350

-247400

-969216

-5570

-2768736

-174391

-1161218

-242665

-3064086

-421791

-1161218 -242665 -3064086 -421791

-14128

-4346

-21887

-11829

367

-47718

-51665

28587

6503 -4110 20847 1808 -26756 -8456 -24118 -9654 -1187974 -251121 -3088204 -431445 0 0 0 0

-1187974

-251121

-3088204

-431445

-0.06

-1.18

-0.17

-2.03

18890670

213001

18121314

213001

-1187974 -251121 -3088204 -431445 -3 -15771 -4841 -25550

-1187977

-266892

-3093045

-456995

-3088204 -431445 8293 1878 43373 4399 0 -367 2074736 0 455032 0 0 -6443 17585 -25689

-1777

-2577

0 1087 0 23800

14202

-45779 7430 -536741 -413725 -474 25317

-474

25317

735913 531798 -34547 0

701366

531798

-4841 -25550 159310 67206 115449 14411 274759 56067 456000 0 193 0

274759

115449

8212

25797

282971

141246

17735

21120

300706

162366

48204

90705

22786 25612 3081 3480

21887

19285

186336 119974 29719 0 222377 29719 534390 288775

534390

288775

1948

1533

-24178 -19337

11738066

8752711

-11949520

-8861316

-233684

-126409

300706

162366

Note 1. The Company Organizational Background Emerald Medical Applications Corp. ("the Company") (f/k/a Zaxis International Inc.) was incorporated in Ohio in 1989, it's fiscal year end is December 31st. On August 25, 1995, The Company merged with a subsidiary of The InFerGene Company ("InFerGene") and InFerGene changed its name to The Company International Inc. InFerGene was incorporated in California in 1984 and subsequently changed its domicile in connection with the merger into The Company to Delaware in 1985. Operations ceased operations in 2002. In November 2002, the Company and its subsidiaries filed a petition for bankruptcy in the U.S. Bankruptcy Court Northern District of Ohio. On October 13, 2004, the Company emerged from bankruptcy. On July 14, 2015 the closing of the Share Exchange Agreement was held (the "Closing") and as a result, Emerald Medical Applications Ltd. became a wholly-owned subsidiary of the Registrant. Pursuant to the Closing of the Share Exchange Agreement, the Company issued 5,474,545 shares of its common stock, par value $0.0001 (the "Shares" or "Common Stock") to Lior Wayn, Emerald's CEO and the sole holder of Emerald Medical Applications Ltd.'s ordinary Shares, representing 40.58% of the company's 13,489,905 outstanding Shares, in exchange for 100% of Emerald Medical Applications Ltd.'s ordinary Shares. Subsequently to the Closing Mr. Lior Wayn has been appointed as the Company's CEO, and has been granted considerable influence on the appointment of new directors thereby creating a new management structure for the company replacing the old management. Additionally Mr. Wayn is to receive additional shares in the future contingent on the Company achieving commercial milestone. Thus the new management, headed by Mr. Wayn, is considered to be in control of more than 50% of the company and with the ability to make all management decisions. Emerald is a company organized under the laws of the State of Israel on February 17, 2010. Emerald is digital health Startup Company engaged in the development, sale and service of imaging solutions utilizing its proprietary DermaCompare software that it developed for use in derma imaging and analytics ("DermaCompare"). Emerald believes that its proprietary DermaCompare software represents an advancement in skin cancer screening that should enable physicians to more readily identify and monitor changes in their patients' skin characteristics. Emerald's DermaCompare solution allows dermatologists and other medical care professionals, using a set of 25 total body photography ("TBP"), to capture sets of skin lesion images with, among other devices, digital cameras, camera-equipped smartphones or tablets. These images are then transmitted online and are remotely analyzed by professionals using our DermaCompare software. Emerald's sales and marketing plan is to sell licenses for our imaging software to: NHSs, HMOs, health insurance companies, hospitals and medical clinics through distributers, health care channel partners or directly through independent salespersons and/or web purchase to dermatologists and other physicians (GPs) that we expect to purchase licenses based on the number of potential numbers of patients. Basis of Presentation The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. The Company has not established any source of revenue to cover its operating costs, and as such, has incurred operating losses since inception. Further, as of June 30, 2016, the cash resources of the Company were insufficient to meet its current business plan, and the Company had negative working capital. These and other factors raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern. The Company elected December 31 as its fiscal year end. Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates. Cash and Cash Equivalents For financial statement presentation purposes, the Company considers those short-term, highly liquid investments with original maturities of three months or less to be cash or cash equivalents. There were no cash equivalents as of June 30, 2016 and December 31, 2015. Other Receivables The company treats VAT refunds claimed resulting from excess VAT paid over VAT received as other receivables, amount shown as other receivables as of June 30, 2016 was $8,212. Currency Translation and other Comprehensive Income Balance sheet items are translated using all current translation method for self-contained foreign operations (where functional currency = foreign currency) whereby assets and liabilities are translated using the exchange rate on the date of the balance sheet. It translates revenues, expenses, and net income using the average exchange rate during the period. The foreign exchange adjustment that results from applying the all-current method appears in other comprehensive income, a separate shareholders' equity account, and does not affect net income each period. Property and Equipment New property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally 5 years. Expenditures for renewals and betterments are capitalized. Expenditures for minor items, repairs and maintenance are charged to operations as incurred. Gain or loss upon sale or retirement due to obsolescence is reflected in the operating results in the period the event takes pla ce. Valuation of Long-Lived Assets We review the recoverability of our long-lived assets including equipment, goodwill and other intangible assets, when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on our ability to recover the carrying value of the asset from the expected future pre-tax cash flows (undiscounted and without interest charges) of the related operations. If these cash flows are less than the carrying value of such asset, an impairment loss is recognized for the difference between estimated fair value and carrying value. Our primary measure of fair value is based on discounted cash flows. The measurement of impairment requires management to make estimates of these cash flows related to long-lived assets, as well as other fair value determinations. Stock Based Compensation Stock-based awards are accounted for using the fair value method in accordance with ASC 718, Share-Based Payments. Our primary type of share-based compensation consists of stock options. We use the Black-Scholes option pricing model in valuing options. The inputs for the valuation analysis of the options include the market value of the Company's common stock, the estimated volatility of the Company's common stock, the exercise price of the warrants and the risk free interest rate. Accounting For Obligations And Instruments Potentially To Be Settled In The Company's Own Stock: We account for obligations and instruments potentially to be settled in the Company's stock in accordance with FASB ASC 815, Accounting for Derivative Financial Instruments. This issue addresses the initial balance sheet classification and measurement of contracts that are indexed to, and potentially settled in, the Company's own stock. Fair Value Measurements The Company adopted the FASB standard related to fair value measurement at inception. The standard defines fair value, establishes a framework for measuring fair value and expands disclosure of fair value measurements. The standard applies under other accounting pronouncements that require or permit fair value measurements and, accordingly, does not require any new fair value measurements. The standard clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the standard established a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows. Level 1. Observable inputs such as quoted prices in active markets; Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The Company values its derivative instruments related to embedded conversion features and warrants from the issuance of convertible debentures in accordance with the Level 3 guidelines. For the six-month period ended June 30, 2016 and the twelve month period ending December 31, 2015, the following table reconciles the beginning and ending balances for financial instruments that are recognized at fair value in these consolidated financial statements. The fair value of embedded conversion features that have floating conversion features and tainted common stock equivalents (warrants and convertible debt) are estimated using a Binomial Lattice model. The key inputs to this valuation model as of December 31, 2015, were: Volatility of 143.9% for the six-month period ended June 30, 2016 and 132.4% for the twelve months period ending December 31, 2015, inherent term of instruments equal to the remaining contractual term, quoted closing stock prices on valuation dates, and various settlement scenarios and probability percentages summing to 100%.   Fair Value Measurements at June 30, 2016   <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100.0%;border-collapse:collapse'> <tr align="left"> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Level 3 - Derivative liabilities from: </td> <td valign="bottom" style='padding:0'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Balance at June 30, 2016 </td> <td valign="bottom" style='padding:0'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> New Issuances </td> <td valign="bottom" style='padding:0'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Settlements </td> <td valign="bottom" style='padding:0'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Change in Fair Value </td> </tr> <tr align="left"> <td width="27%" valign="bottom" style='width:27.0%;background:white;padding:0'> Convertible Note </td> <td width="2%" valign="bottom" style='width:2.0%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> $ </td> <td width="16%" valign="bottom" style='width:16.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> - </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> $ </td> <td width="6%" valign="bottom" style='width:6.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> - </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> $ </td> <td width="6%" valign="bottom" style='width:6.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> - </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'>   </td> <td width="9%" valign="bottom" style='width:9.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> - </td> </tr> <tr align="left"> <td width="276" style='border:none'></td> <td width="20" style='border:none'></td> <td width="9" style='border:none'></td> <td width="163" style='border:none'></td> <td width="9" style='border:none'></td> <td width="10" style='border:none'></td> <td width="60" style='border:none'></td> <td width="9" style='border:none'></td> <td width="12" style='border:none'></td> <td width="70" style='border:none'></td> <td width="9" style='border:none'></td> <td width="9" style='border:none'></td> <td width="91" style='border:none'></td> </tr> </table>   Fair Value Measurements at December 31, 2015   <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100.0%;border-collapse:collapse'> <tr align="left"> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Level 3 - Derivative liabilities from: </td> <td valign="bottom" style='padding:0'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Balance at December 31, 2015 </td> <td valign="bottom" style='padding:0'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> New Issuances </td> <td valign="bottom" style='padding:0'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Extinguishment </td> <td valign="bottom" style='padding:0'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Change in Fair Value </td> </tr> <tr align="left"> <td width="27%" valign="bottom" style='width:27.0%;background:white;padding:0'> Convertible Note </td> <td width="2%" valign="bottom" style='width:2.0%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> $ </td> <td width="16%" valign="bottom" style='width:16.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> - </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> $ </td> <td width="6%" valign="bottom" style='width:6.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> - </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> $ </td> <td width="6%" valign="bottom" style='width:6.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> (20,532) </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'>   </td> <td width="9%" valign="bottom" style='width:9.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> - </td> </tr> <tr align="left"> <td width="273" style='border:none'></td> <td width="17" style='border:none'></td> <td width="9" style='border:none'></td> <td width="158" style='border:none'></td> <td width="7" style='border:none'></td> <td width="10" style='border:none'></td> <td width="58" style='border:none'></td> <td width="4" style='border:none'></td> <td width="16" style='border:none'></td> <td width="95" style='border:none'></td> <td width="6" style='border:none'></td> <td width="7" style='border:none'></td> <td width="89" style='border:none'></td> </tr> </table>   Changes in the unobservable input values would likely cause material changes in the fair value of the Company's Level 3 financial instruments. The significant unobservable input used in the fair value measurement is the estimation for probability percentages assigned to future expected settlement possibilities. A significant increase (decrease) in this distribution of percentages would result in a higher (lower) fair value measurement. The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of June 30, 2016 and December 31, 2015:   Fair Value Measurements at June 30, 2016     <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="80%" style='width:80.0%;border-collapse:collapse'> <tr align="left"> <td valign="bottom" style='padding:0in 0in 1.5pt 0in'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Level 3 </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0'> Assets </td> <td valign="bottom" style='background:white;padding:0'>   </td> <td valign="bottom" style='background:white;padding:0'>   </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in'> Total Assets </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> $ </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> - </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in'>   </td> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in'>   </td> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in'>   </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0'> Liabilities </td> <td valign="bottom" style='background:white;padding:0'>   </td> <td valign="bottom" style='background:white;padding:0'>   </td> </tr> <tr align="left"> <td width="78%" valign="bottom" style='width:78.0%;background:white;padding:0in 0in 1.5pt 0in'> Derivative liability </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> $ </td> <td width="18%" valign="bottom" style='width:18.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> - </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0in 0in 2.5pt 0in'> Total Liabilities </td> <td valign="bottom" style='border:none;border-bottom:double black 2.25pt;background:white;padding:0'> $ </td> <td valign="bottom" style='border:none;border-bottom:double black 2.25pt;background:white;padding:0'> - </td> </tr> </table> </div>   Fair Value Measurements at December 31, 2015   <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="80%" style='width:80.0%;border-collapse:collapse'> <tr style='height:.6pt'> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in;height:.6pt'></td> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in;height:.6pt'></td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0;height:.6pt'> Level 3 </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0'> Assets </td> <td valign="bottom" style='background:white;padding:0'>   </td> <td valign="bottom" style='background:white;padding:0'>   </td> </tr> <tr align="left"> <td width="78%" valign="bottom" style='width:78.0%;background:white;padding:0in 0in 1.5pt 0in'> Total Assets </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> $ </td> <td width="18%" valign="bottom" style='width:18.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> - </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0'>   </td> <td valign="bottom" style='background:white;padding:0'>   </td> <td valign="bottom" style='background:white;padding:0'>   </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0'> Liabilities </td> <td valign="bottom" style='background:white;padding:0'>   </td> <td valign="bottom" style='background:white;padding:0'>   </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in'> Derivative liability </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> $ </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> - </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0in 0in 2.5pt 0in'> Total Liabilities </td> <td valign="bottom" style='border:none;border-bottom:double black 2.25pt;background:white;padding:0'> $ </td> <td valign="bottom" style='border:none;border-bottom:double black 2.25pt;background:white;padding:0'> - </td> </tr> </table> </div>     The fair values of our debts are deemed to approximate book value, and are considered Level 2 inputs as defined by ASC Topic 820-10-35. There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the six months ended June 30, 2016 or the year ended December 31, 2015. The Company had no other assets or liabilities valued at fair value on a recurring or non-recurring basis as of June 30, 2016 or December 31, 2015. Earnings per Common Share We compute net income (loss) per share in accordance with ASC 260, Earning per Share. ASC 260 requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. All per share disclosures retroactively reflect shares outstanding or issuable as though the reverse split had occurred January 1, 2012. Income Taxes We have adopted FASB ASC 740, Accounting for Income Taxes. Pursuant to ASC 740, we are required to compute tax asset benefits for net operating losses carried forward. The potential benefits of net operating losses have not been recognized in these financial statements because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years. We must make certain estimates and judgments in determining income tax expense for financial statement purposes. These estimates and judgments occur in the calculation of certain tax assets and liabilities, which arise from differences in the timing of recognition of revenue and expense for tax and financial statement purposes. Deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax basis of assets and liabilities using the tax rates and laws in effect when the differences are expected to reverse. ASC 740 provides for the recognition of deferred tax assets if realization of such assets is more likely than not to occur. Realization of our net deferred tax assets is dependent upon our generating sufficient taxable income in future years in appropriate tax jurisdictions to realize benefit from the reversal of temporary differences and from net operating loss, or NOL, carryforwards. We have determined it more likely than not that these timing differences will not materialize and have provided a valuation allowance against substantially all of our net deferred tax asset. Management will continue to evaluate the realizability of the deferred tax asset and its related valuation allowance. If our assessment of the deferred tax assets or the corresponding valuation allowance were to change, we would record the related adjustment to income during the period in which we make the determination. Our tax rate may also vary based on our results and the mix of income or loss in domestic and foreign tax jurisdictions in which we operate. In addition, the calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax regulations. We recognize liabilities for anticipated tax audit issues in the U.S. and other tax jurisdictions based on our estimate of whether, and to the extent to which, additional taxes will be due. If we ultimately determine that payment of these amounts is unnecessary, we will reverse the liability and recognize a tax benefit during the period in which we determine that the liability is no longer necessary. We will record an additional charge in our provision for taxes in the period in which we determine that the recorded tax liability is less than we expect the ultimate assessment to be. ASC 740 which requires recognition of estimated income taxes payable or refundable on income tax returns for the current period and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized. Uncertain Tax Positions When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of FASB ASC 740-10, Accounting for Uncertain Income Tax Positions, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Our federal and state income tax returns are open for fiscal years ending on or after December 31, 2011. We are not under examination by any jurisdiction for any tax year. At June 30, 2016 we had no material unrecognized tax benefits and no adjustments to liabilities or operations were required under FIN 48. Recent Accounting Pronouncements In September, 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805) ("ASU 2015-16"). Topic 805 requires that an acquirer retrospectively adjust provisional amounts recognized in a business combination, during the measurement period. To simplify the accounting for adjustments made to provisional amounts, the amendments in the Update require that the acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amount is determined. The acquirer is required to also record, in the same period's financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date. In addition an entity is required to present separately on the face of the income statement or disclose in the notes to the financial statements the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date. ASU 2015-16 is effective for fiscal years beginning December 15, 2015. The adoption of ASU 2015-016 is not expected to have a material effect on the Company's consolidated financial statements. In August, 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date ("ASU 2015-14"). The amendment in this ASU defers the effective date of ASU No. 2014-09 for all entities for one year. Public business entities, certain not-for-profit entities, and certain employee benefit plans should apply the guidance in ASU 2014-09 to annual reporting periods beginning December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 31, 2016, including interim reporting periods with that reporting period. In April 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2015-03, Interest-Imputation of Interest (Subtopic 835-30) ("ASU 2015-03"), which changes the presentation of debt issuance costs in financial statements. ASU 2015-03 requires an entity to present such costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. Amortization of the costs will continue to be reported as interest expense. It is effective for annual reporting periods beginning after December 15, 2016. Early adoption is permitted. The new guidance will be applied retrospectively to each prior period presented. The Company is currently in the process of evaluating the impact of adoption of ASU 2015-03 on its balance sheets Going Concern The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. The Company has not established any source of revenue to cover its operating costs, and as such, has incurred an operating loss since inception. Further, as of June 30, 2016, the cash resources of the Company were insufficient to meet its current business plan, and the Company had negative working capital. These and other factors raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

Note 2. Stockholders' Equity. On January 8, 2015 the shareholders approved a resolution to increase the authorized common shares from 100,000,000 to 490,000,000 shares. All other provisions of the common shares remain unchanged. Also on that date, the Company declared a reverse split of common stock at the ration of 1:4. The stock split was effective January 8, 2015 for holders of record as of that date. Except as otherwise noted, all share, option and warrant numbers have been restated to give retroactive effect to this split. All per share disclosures retroactively reflect shares outstanding or issuable as though the reverse split had occurred at January 1, 2012. Recent Issuances of Common Stock Between January 15, 2015 and March 15, 2015, the Company sold a total of 2,052,000 units for cash consideration of $780,000 at a price of $0.40 (the "Units"), each unit comprised of one share of common stock and one Class A warrant exercisable at $0.80 per share with a term 24 month. The relative fair value of the stock with embedded warrants was $351,433 for the common stock and $428,567 for the class A warrants. The warrants were valued using the Black-Scholes model with 153% volatility and discount rates ranging between 0.44% to 0.7%. These units were issued as stock payable and the cash from sale of units was not received for the sale of stock pre-reverse merger. Between April 1, 2015 and June 29, 2015, the Company sold a total of 1,012,500 units for cash consideration of $405,000 at a price of $0.40 (the "Units"), each unit comprised of one share of common stock and one Class A warrant exercisable at $0.80 per share with a term 24 month. The relative fair value of the stock with embedded warrants was $158,123 for the common stock and $246,877 for the class A warrants. The warrants were valued using the Black-Scholes model with volatility ranging between163% - 177% and discount rates ranging between 0.54% to 0.71%. These units were issued as stock payable and the cash from sale of units was not received for the sale of stock pre-reverse merger. Between July 1, 2015 and September 30, 2015, the Company sold a total of 140,000 units for cash consideration of $15,000 at price of $0.107 (the "Units"), each unit comprised of one share of common stock and one Class A warrant exercisable at $0.80 per share with a term 24 month. The relative fair value of the stock with embedded warrants was $4,294 for the common stock and $10,706 for the class A warrants. The warrants were valued using the Black-Scholes model with volatility of 153% and discount rates of 0.61%. These units were issued as stock payable and the cash from sale of units was not received for the sale of stock pre-reverse merger. Between July 1, 2015 and September 30, 2015, the Company sold a total of 862,500 units for cash consideration of $345,000 at price of $0.40 (the "Units"), each unit comprised of one share of common stock and one Class A warrant exercisable at $0.80 per share with a term 24 month. The relative fair value of the stock with embedded warrants was $118,415 for the common stock and $226,585 for the class A warrants. The warrants were valued using the Black-Scholes model with volatility ranging between 153% - 182% and discount rates ranging between 0.54% to 0.71%. Of these units $65,000 were issued as stock payable and the cash from sale of units was not received for the sale of stock pre-reverse merger and $280,000 cash was received subsequent to Closing of the reverse merger. On July 16, 2015 and August 6, 2015, the company issue 517,900 shares to one service provider and 100,000 shares to two service providers, respectively, for services valued at a total value of $617,900, arrived at using the stock price on date of grant of $1.00 per Nasdaq.com. On July 16, 2015, 5 Emerald debt holders in amount of $87,910 converted their debt into 274,719 units at a conversion price of $0.32 per unit, each unit comprised of one share of common stock and one Class A warrant exercisable at $0.80 per share with a term 24 month. The Loss on Settlement of Debt recorded was $678,027. On July 14, 2015 the Company issued Emerald's CEO and founder, Lior Wayn, 5,474,545 shares as per the share purchase agreement valued at $877,380, valued on the date of grant for the price of common stock. On July 16, 2015 consultants were issued 2,500,000 Class B Warrants exercisable for a two-year period to acquire one (1) share of Common Stock at a price of $0.40 per share The fair value of these warrants is $2,199,507. The warrants were valued using the Black-Scholes model with volatility of 182% and discount rate of 0.67%. The Class B warrants are fully vested and were accordingly included in expenses as stock based compensation. On July 16, 2015 consultants were issued 2,536,247 Class C Warrants exercisable for a 90 day period, commencing 90 days after the effective date of this Registration Statement, at an exercise price of $0.40 to acquire one (1) share of Common Stock and one (1) Class A Warrant at an exercise price of $0.80. The fair value of these warrants is $3,143,581. The warrants were valued using the Black-Scholes model with volatility of 182% and discount rate of 0.67%. The Class C warrants are fully vested and were accordingly included in expenses as stock based compensation. On November 17, 2015 the Company sold 250,000 units for cash consideration of $100,000 at price of $0.40 (the "Units"), each unit comprised of one share of common stock and one Class A warrant exercisable at $0.80 per share with a term 24 month. The relative fair value of the stock with embedded warrants was $41,304 for the common stock and $58,696 for the class A warrants. The warrants were valued using the Black-Scholes model with volatility ranging between 149% and discount rate of 0.50%. These warrants are fully vested and the fair value and included as stock based compensation on the prior year retained earnings. Between November 5, 2015 and November 16, 2015 the company issue 268,084 shares to three service provider and for services valued at a total value of $268,084, arrived at using the stock price on date of grant of $1.00 per Nasdaq.com. On October 1, 2015, the Company granted a total of 534,400 stock options (the "Options") to three company employees. The options vest over 5 quarters and are exercisable at prices ranging from $0.01 to $0.40 per Share. The options were valued using the Black-Scholes model with 149% volatility and 0.67% discount rate for a total value of $528,857. Of this amount, $397,547 was expensed as of December 31, 2015 and $42,394 as of March 31, 2016. An additional $42,394 was expensed during the three-month period ended June 30, 2016. On January 26, 2016 and March 17, 2016, the Company issued 125,000 shares to one service provider and 50,000 shares to two service providers, respectively, for services valued at a total value of $251,250, arrived at using the stock price on date of grant of $1.75 and $0.65, respectively, per Nasdaq.com. On February 18, 2016, the Company issued 1,195,000 shares to three acting directors, for services valued at a total value of $1,194,403, arrived at using the stock price on date of grant of $1.00 per Nasdaq.com. On January 26, 2016, consultants that were previously issued 2,500,000 Class B Warrants exercisable for a two-year period to acquire one (1) share of Common Stock at a price of $0.40 per share, exercised the warrants on a cashless basis resulting in 1,928,572 shares issued with no additional related expense booked. On February 11 and 18, 2016, the Company granted a total of 403,333 stock options (the "Options") to three company employees. The options vest over periods of between 1 and 8 quarters and are exercisable at prices ranging from $0.01 to $0.40 per Share. The options were valued using the Black-Scholes model with 157% volatility and 0.56% discount rate for a total value of $400,914. Of this amount, $231,920 was expensed during the three-months ended March 31, 2016 and $48,711 during the three-months ended June 30, 2016. On March 24, 2016, a convertible note payable was issued to GoldMed Ltd. The warrants were valued at a fair value of $56,030. The note included a beneficial conversion feature which resulted in a $75,000 discount recorded as a reduction of debt and an increase to additional paid in capital. On April 5, 2016, the Company issued 150,000 shares to one service provider for services valued at $105,000 based on the Company's stock price of $0.70 per share on the date of issuance. On May 10, 2016, the Company issued 41,667 shares to one service provider for services valued at $72,911 based on the Company's stock price of $1.75 per share on the date of issuance. On May 18, 2016, the Company issued 150,000 shares to one service provider for services valued at $102,000 based on the Company's stock price of $0.68 per share on the date of issuance. On June 28, 2016, the Company issued 175,000 shares to one service provider for services valued at $122,500 based on the Company's stock price of $0.70 per share on the date of issuance. On June 30, 2016, the Company issued 333,333 shares to one service provider for services valued at $226,666 based on the Company's stock price of $0.68 per share on the date of issuance. On June 6, 2016, a convertible note payable was issued to Alpha Capital. The attached warrants were valued at a fair value of $440,000. The note included a beneficial conversion feature which resulted in a $300,000 discount recorded as a reduction of debt and an increase to additional paid in capital. On April 11, 2016, a convertible note payable was issued to Maz Partner. The attached warrants were valued at a fair value of $80,000. The note included a beneficial conversion feature which resulted in a $46,000 discount recorded as a reduction of debt and an increase to additional paid in capital. On June 30, 2016, a convertible note payable was issued to Ilan Malka. The attached warrants were valued at a fair value of $40,000. The note included a beneficial conversion feature which resulted in a $35,000 discount recorded as a reduction of debt and an increase to additional paid in capital. On April 14, 2016, the Company granted a total of 450,000 stock options (the "Options") to one Company director. The options vest over periods of between 1 and 3 quarters and are exercisable at $0.60 per share. The options were valued using the Black-Scholes model with 233% volatility and 0.56% discount rate for a total value of $268,839. The Company expensed $89,613 during the three-months ended June 30, 2016 related to these options.

Note 3. Related Party Transactions On July 16, 2015 5 Emerald debt holders in amount of $87,910 converted their debt into 274,719 units at a conversion price of $0.32 per unit, each unit comprised of one share of common stock and one Class A warrant exercisable at $0.80 per share with a term 24 month. The Loss on Settlement of Debt recorded was $678,027. On July 14, 2015 the Company issued Emerald's CEO and founder, Lior Wayn, 5,474,545 shares as per the share purchase agreement valued at $877,380, valued on the date of grant for the price of common stock. The company's CEO, Lior Wayn was owed $3,310 and $3,480 payable as of June 30, 2016 and December 31, 2015, respectively. Following Closing of the reverse merger, $490,000 loan from Zaxis International Inc. to Emerald Medical Applications Ltd. was rendered an intercompany loan and as such was written off. On February 18, 2016, the Company issued 1,195,000 shares to three acting directors, for services valued at a total value of $1,194,403, arrived at using the stock price on date of grant of $1.00 per Nasdaq.com.

Note 10. Accounts Payable and Accrued Liabilities As of June 30, 2016 and December 31, 2015, the Company had Accounts payable and accrued liabilities of $48,204 and $90,705, respectively.

Note 5. Notes Payable. Convertible Notes Payable On March 24, 2016, the Company issued a convertible promissory note to GoldMed Ltd. in the amount of $75,000. The Convertible Note is convertible to 187,500 units at $0.40 (the "Units"), each unit comprised of one share of common stock and one Class A warrant exercisable at $0.80 per share with a term 24 months. Since the market price on the date of issuance was higher than the conversion price, a beneficial conversion feature was calculated at $78,750, but only $75,000 was recorded. $20,137 was recorded as amortization expense of for the period ending June 30, 2016, compared to amortization expense of $0 as of December 31, 2015. On June 20, 2016, a $400,000 convertible note payable and 200,000 warrants exercisable at $0.80 per share with a term of 24 months was issued to Alpha Capital. The note included a beneficial conversion feature which resulted in a $300,000 discount recorded as a reduction of debt and an increase to additional paid in capital. The Company recorded an amortization expense of $8,219 related to this note. On March 31, 2016, a $80,000 convertible note payable and 200,000 warrants exercisable at $0.80 per share with a term of 24 months was issued to Maz Partner. The note included a beneficial conversion feature which resulted in a $46,000 discount recorded as a reduction of debt and an increase to additional paid in capital. The Company recorded an amortization expense of $11,468 related to this note. On May 24, 2016, a convertible note payable was issued to Ilan Malka. The note included a beneficial conversion feature which resulted in a $35,000 discount recorded as a reduction of debt and an increase to additional paid in capital. The Company recorded an amortization expense of $3,548 related to this note.

Note 6. Payable - Not Convertible On July 8, 2014 the company issued a convertible promissory note to Axel Springer Plug & Play Accelerator GmbH (the "Holder"), in the amounts of $29,719. The Convertible Notes are convertible at the lessor of a market based discounted and a fixed rate derived from a fixed market cap. The Holders have the right following the Date of Issuance, and until any time until the convertible Promissory Note is fully paid, to convert any outstanding and unpaid principal portion of the Convertible Promissory Note, and accrued interest, into fully paid and non-assessable shares of Common Stock. Holder was not issued warrants with the Convertible Promissory Note. As of December 31, 2015 this note is no longer convertible since pursuant to the loan agreement the in the event that prior to December 31,2015 (the "Maturity Date"), the Company shall consummate a financing round led by unaffiliated investors in the amount of at least Euro 200,000, at a Company pre-money valuation on a fully diluted basis of at least Euro 750,000 (a "Qualified Round"), the Holder shall be entitled (but not obligated) to convert the entire loan amount into the most senior class of shares of the Company issued in such Qualified Round, based on a price per share equal to the lower of the price per share reflected by a Company pre-money valuation on a fully diluted basis calculated at the time of conversion equal to Euro 1,500,000; or - price per share which reflects a 20% discount on the lowest price per share issued pursuant to such Qualified Round. If upon the occurrence of such event the note holder elects not to convert upon receiving notice of such event, then the loan becomes non-convertible. On January 14 and 16, 2015, we issued two promissory notes in the amount of $15,000 each to two different unaffiliated party in consideration for cash transferred to the Company (the "January 2015 Notes"). The January 2015 Notes bears interest at the rate of 1% per annum, are due and payable on January 14 and 16, 2016 and are not convertible to common stock. One of the notes was repaid in full on March 3, 2015 with interest due waived the by the debtor, and the second note was repaid on April 22, 2015 with interest due waived the by the debtor. During the second quarter of 2015, an agreement was reached with the holder of $120,979 advance payable note to settle the full amount due for $30,000 and interest due. The settlement with all note holders resulted in $528 loss on debt settlement due to the payment being higher than principal and accrued interest as of that date as well as a charge of $90,979 considered a contribution of capital due to the fact that note holder, IMWT, was a related party. We concluded that these notes have a stated rate of interest that is different from the rate of interest that is appropriate for this type of debt at the date of the transaction. Accordingly, the company imputed interest at an appropriate rate estimated at 8% as prescribed under FASB ASC 835. The resultant charge of $6,280 for the period ending December 31, 2014 and $4,113 for the period ending March 31, 2015 to interest expense was considered a contribution of capital and was recorded in additional paid in capital. On November 16, 2014 four individuals loaned amount to company, totaling $87,910 with maturity dates of November 16, 2015 and bearing an interest rate of 8% per annum, these notes were fully converted on July 16, 2015 to Company shares of commons stock and warrants as described in Note 3. On March 9, 2016 four individuals lent the company a total of $34,547 with maturity dates of November 16, 2015 and bearing an interest rate of 8% per annum. As of June 30, 2016, the loan was fully repaid. For the periods ended June 30, 2016 and December 31, 2015, the Company has recognized $21,420 and $19,285, respectively, in accrued interest expense related to the stated interest rate on the notes. Interest expense for the periods ended June 30, 2016 and June 30, 2015, respectively, were $21,887 and $11,829, as well as $43,372 and $0 from the amortization of debt discount.

Note 7. Commitments and Contingencies The Company received research and development grants from the State of Israel according to guidelines and procedures of the Office of the Chief Scientist of the Ministry of Industry and Trade. According to the agreement, the Company is obliged to pay royalties on the sale of products developed with the participation of the Chief Scientist. The royalty rate is 3.5% and the total royalties will not exceed the amount of the grants. As of June 30, 2016, the Company had an outstanding contingent liability to pay royalties in the amount of $186,335, with $15,795 in accrued interest.

<div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="80%" style='width:80.0%;border-collapse:collapse'> <tr align="left"> <td valign="bottom" style='padding:0in 0in 1.5pt 0in'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Level 3 </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0'> Assets </td> <td valign="bottom" style='background:white;padding:0'>   </td> <td valign="bottom" style='background:white;padding:0'>   </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in'> Total Assets </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> $ </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> - </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in'>   </td> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in'>   </td> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in'>   </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0'> Liabilities </td> <td valign="bottom" style='background:white;padding:0'>   </td> <td valign="bottom" style='background:white;padding:0'>   </td> </tr> <tr align="left"> <td width="78%" valign="bottom" style='width:78.0%;background:white;padding:0in 0in 1.5pt 0in'> Derivative liability </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> $ </td> <td width="18%" valign="bottom" style='width:18.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> - </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0in 0in 2.5pt 0in'> Total Liabilities </td> <td valign="bottom" style='border:none;border-bottom:double black 2.25pt;background:white;padding:0'> $ </td> <td valign="bottom" style='border:none;border-bottom:double black 2.25pt;background:white;padding:0'> - </td> </tr> </table> </div>   Fair Value Measurements at December 31, 2015   <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="80%" style='width:80.0%;border-collapse:collapse'> <tr style='height:.6pt'> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in;height:.6pt'></td> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in;height:.6pt'></td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0;height:.6pt'> Level 3 </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0'> Assets </td> <td valign="bottom" style='background:white;padding:0'>   </td> <td valign="bottom" style='background:white;padding:0'>   </td> </tr> <tr align="left"> <td width="78%" valign="bottom" style='width:78.0%;background:white;padding:0in 0in 1.5pt 0in'> Total Assets </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> $ </td> <td width="18%" valign="bottom" style='width:18.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> - </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0'>   </td> <td valign="bottom" style='background:white;padding:0'>   </td> <td valign="bottom" style='background:white;padding:0'>   </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0'> Liabilities </td> <td valign="bottom" style='background:white;padding:0'>   </td> <td valign="bottom" style='background:white;padding:0'>   </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in'> Derivative liability </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> $ </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> - </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0in 0in 2.5pt 0in'> Total Liabilities </td> <td valign="bottom" style='border:none;border-bottom:double black 2.25pt;background:white;padding:0'> $ </td> <td valign="bottom" style='border:none;border-bottom:double black 2.25pt;background:white;padding:0'> - </td> </tr> </table> </div>

Note 9. Other Receivables As of June 30, 2016 and December 31, 2015 the Company had other receivables of $8,212 and $25,797, respectively, which represent VAT refunds claimed resulting from excess VAT paid over VAT received.

Note 4. Employee Payable. For the periods ended June 30, 2016 and December 31, 2015 the Company had $25,867 and $25,612, respectively, in employee payable related to the monthly wages payable to the company's employees.

Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.

Cash and Cash Equivalents For financial statement presentation purposes, the Company considers those short-term, highly liquid investments with original maturities of three months or less to be cash or cash equivalents. There were no cash equivalents as of June 30, 2016 and December 31, 2015.

Other Receivables The company treats VAT refunds claimed resulting from excess VAT paid over VAT received as other receivables, amount shown as other receivables as of June 30, 2016 was $8,212.

Currency Translation and other Comprehensive Income Balance sheet items are translated using all current translation method for self-contained foreign operations (where functional currency = foreign currency) whereby assets and liabilities are translated using the exchange rate on the date of the balance sheet. It translates revenues, expenses, and net income using the average exchange rate during the period. The foreign exchange adjustment that results from applying the all-current method appears in other comprehensive income, a separate shareholders' equity account, and does not affect net income each period.

Property and Equipment New property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally 5 years. Expenditures for renewals and betterments are capitalized. Expenditures for minor items, repairs and maintenance are charged to operations as incurred. Gain or loss upon sale or retirement due to obsolescence is reflected in the operating results in the period the event takes pla

Valuation of Long-Lived Assets We review the recoverability of our long-lived assets including equipment, goodwill and other intangible assets, when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on our ability to recover the carrying value of the asset from the expected future pre-tax cash flows (undiscounted and without interest charges) of the related operations. If these cash flows are less than the carrying value of such asset, an impairment loss is recognized for the difference between estimated fair value and carrying value. Our primary measure of fair value is based on discounted cash flows. The measurement of impairment requires management to make estimates of these cash flows related to long-lived assets, as well as other fair value determinations.

Stock Based Compensation Stock-based awards are accounted for using the fair value method in accordance with ASC 718, Share-Based Payments. Our primary type of share-based compensation consists of stock options. We use the Black-Scholes option pricing model in valuing options. The inputs for the valuation analysis of the options include the market value of the Company's common stock, the estimated volatility of the Company's common stock, the exercise price of the warrants and the risk free interest rate.

Accounting For Obligations And Instruments Potentially To Be Settled In The Company's Own Stock: We account for obligations and instruments potentially to be settled in the Company's stock in accordance with FASB ASC 815, Accounting for Derivative Financial Instruments. This issue addresses the initial balance sheet classification and measurement of contracts that are indexed to, and potentially settled in, the Company's own stock.

Fair Value Measurements The Company adopted the FASB standard related to fair value measurement at inception. The standard defines fair value, establishes a framework for measuring fair value and expands disclosure of fair value measurements. The standard applies under other accounting pronouncements that require or permit fair value measurements and, accordingly, does not require any new fair value measurements. The standard clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the standard established a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows. Level 1. Observable inputs such as quoted prices in active markets; Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The Company values its derivative instruments related to embedded conversion features and warrants from the issuance of convertible debentures in accordance with the Level 3 guidelines. For the six-month period ended June 30, 2016 and the twelve month period ending December 31, 2015, the following table reconciles the beginning and ending balances for financial instruments that are recognized at fair value in these consolidated financial statements. The fair value of embedded conversion features that have floating conversion features and tainted common stock equivalents (warrants and convertible debt) are estimated using a Binomial Lattice model. The key inputs to this valuation model as of December 31, 2015, were: Volatility of 143.9% for the six-month period ended June 30, 2016 and 132.4% for the twelve months period ending December 31, 2015, inherent term of instruments equal to the remaining contractual term, quoted closing stock prices on valuation dates, and various settlement scenarios and probability percentages summing to 100%.   Fair Value Measurements at June 30, 2016   <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100.0%;border-collapse:collapse'> <tr align="left"> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Level 3 - Derivative liabilities from: </td> <td valign="bottom" style='padding:0'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Balance at June 30, 2016 </td> <td valign="bottom" style='padding:0'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> New Issuances </td> <td valign="bottom" style='padding:0'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Settlements </td> <td valign="bottom" style='padding:0'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Change in Fair Value </td> </tr> <tr align="left"> <td width="27%" valign="bottom" style='width:27.0%;background:white;padding:0'> Convertible Note </td> <td width="2%" valign="bottom" style='width:2.0%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> $ </td> <td width="16%" valign="bottom" style='width:16.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> - </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> $ </td> <td width="6%" valign="bottom" style='width:6.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> - </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> $ </td> <td width="6%" valign="bottom" style='width:6.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> - </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'>   </td> <td width="9%" valign="bottom" style='width:9.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> - </td> </tr> <tr align="left"> <td width="276" style='border:none'></td> <td width="20" style='border:none'></td> <td width="9" style='border:none'></td> <td width="163" style='border:none'></td> <td width="9" style='border:none'></td> <td width="10" style='border:none'></td> <td width="60" style='border:none'></td> <td width="9" style='border:none'></td> <td width="12" style='border:none'></td> <td width="70" style='border:none'></td> <td width="9" style='border:none'></td> <td width="9" style='border:none'></td> <td width="91" style='border:none'></td> </tr> </table>   Fair Value Measurements at December 31, 2015   <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100.0%;border-collapse:collapse'> <tr align="left"> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Level 3 - Derivative liabilities from: </td> <td valign="bottom" style='padding:0'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Balance at December 31, 2015 </td> <td valign="bottom" style='padding:0'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> New Issuances </td> <td valign="bottom" style='padding:0'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Extinguishment </td> <td valign="bottom" style='padding:0'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Change in Fair Value </td> </tr> <tr align="left"> <td width="27%" valign="bottom" style='width:27.0%;background:white;padding:0'> Convertible Note </td> <td width="2%" valign="bottom" style='width:2.0%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> $ </td> <td width="16%" valign="bottom" style='width:16.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> - </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> $ </td> <td width="6%" valign="bottom" style='width:6.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> - </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> $ </td> <td width="6%" valign="bottom" style='width:6.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> (20,532) </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'>   </td> <td width="9%" valign="bottom" style='width:9.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> - </td> </tr> <tr align="left"> <td width="273" style='border:none'></td> <td width="17" style='border:none'></td> <td width="9" style='border:none'></td> <td width="158" style='border:none'></td> <td width="7" style='border:none'></td> <td width="10" style='border:none'></td> <td width="58" style='border:none'></td> <td width="4" style='border:none'></td> <td width="16" style='border:none'></td> <td width="95" style='border:none'></td> <td width="6" style='border:none'></td> <td width="7" style='border:none'></td> <td width="89" style='border:none'></td> </tr> </table>   Changes in the unobservable input values would likely cause material changes in the fair value of the Company's Level 3 financial instruments. The significant unobservable input used in the fair value measurement is the estimation for probability percentages assigned to future expected settlement possibilities. A significant increase (decrease) in this distribution of percentages would result in a higher (lower) fair value measurement. The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of June 30, 2016 and December 31, 2015:   Fair Value Measurements at June 30, 2016     <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="80%" style='width:80.0%;border-collapse:collapse'> <tr align="left"> <td valign="bottom" style='padding:0in 0in 1.5pt 0in'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Level 3 </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0'> Assets </td> <td valign="bottom" style='background:white;padding:0'>   </td> <td valign="bottom" style='background:white;padding:0'>   </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in'> Total Assets </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> $ </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> - </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in'>   </td> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in'>   </td> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in'>   </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0'> Liabilities </td> <td valign="bottom" style='background:white;padding:0'>   </td> <td valign="bottom" style='background:white;padding:0'>   </td> </tr> <tr align="left"> <td width="78%" valign="bottom" style='width:78.0%;background:white;padding:0in 0in 1.5pt 0in'> Derivative liability </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> $ </td> <td width="18%" valign="bottom" style='width:18.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> - </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0in 0in 2.5pt 0in'> Total Liabilities </td> <td valign="bottom" style='border:none;border-bottom:double black 2.25pt;background:white;padding:0'> $ </td> <td valign="bottom" style='border:none;border-bottom:double black 2.25pt;background:white;padding:0'> - </td> </tr> </table> </div>   Fair Value Measurements at December 31, 2015   <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="80%" style='width:80.0%;border-collapse:collapse'> <tr style='height:.6pt'> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in;height:.6pt'></td> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in;height:.6pt'></td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0;height:.6pt'> Level 3 </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0'> Assets </td> <td valign="bottom" style='background:white;padding:0'>   </td> <td valign="bottom" style='background:white;padding:0'>   </td> </tr> <tr align="left"> <td width="78%" valign="bottom" style='width:78.0%;background:white;padding:0in 0in 1.5pt 0in'> Total Assets </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> $ </td> <td width="18%" valign="bottom" style='width:18.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> - </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0'>   </td> <td valign="bottom" style='background:white;padding:0'>   </td> <td valign="bottom" style='background:white;padding:0'>   </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0'> Liabilities </td> <td valign="bottom" style='background:white;padding:0'>   </td> <td valign="bottom" style='background:white;padding:0'>   </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in'> Derivative liability </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> $ </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> - </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0in 0in 2.5pt 0in'> Total Liabilities </td> <td valign="bottom" style='border:none;border-bottom:double black 2.25pt;background:white;padding:0'> $ </td> <td valign="bottom" style='border:none;border-bottom:double black 2.25pt;background:white;padding:0'> - </td> </tr> </table> </div>     The fair values of our debts are deemed to approximate book value, and are considered Level 2 inputs as defined by ASC Topic 820-10-35. There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the six months ended June 30, 2016 or the year ended December 31, 2015. The Company had no other assets or liabilities valued at fair value on a recurring or non-recurring basis as of June 30, 2016 or December 31, 2015.

Earnings per Common Share We compute net income (loss) per share in accordance with ASC 260, Earning per Share. ASC 260 requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. All per share disclosures retroactively reflect shares outstanding or issuable as though the reverse split had occurred January 1, 2012.

Income Taxes We have adopted FASB ASC 740, Accounting for Income Taxes. Pursuant to ASC 740, we are required to compute tax asset benefits for net operating losses carried forward. The potential benefits of net operating losses have not been recognized in these financial statements because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years. We must make certain estimates and judgments in determining income tax expense for financial statement purposes. These estimates and judgments occur in the calculation of certain tax assets and liabilities, which arise from differences in the timing of recognition of revenue and expense for tax and financial statement purposes. Deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax basis of assets and liabilities using the tax rates and laws in effect when the differences are expected to reverse. ASC 740 provides for the recognition of deferred tax assets if realization of such assets is more likely than not to occur. Realization of our net deferred tax assets is dependent upon our generating sufficient taxable income in future years in appropriate tax jurisdictions to realize benefit from the reversal of temporary differences and from net operating loss, or NOL, carryforwards. We have determined it more likely than not that these timing differences will not materialize and have provided a valuation allowance against substantially all of our net deferred tax asset. Management will continue to evaluate the realizability of the deferred tax asset and its related valuation allowance. If our assessment of the deferred tax assets or the corresponding valuation allowance were to change, we would record the related adjustment to income during the period in which we make the determination. Our tax rate may also vary based on our results and the mix of income or loss in domestic and foreign tax jurisdictions in which we operate. In addition, the calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax regulations. We recognize liabilities for anticipated tax audit issues in the U.S. and other tax jurisdictions based on our estimate of whether, and to the extent to which, additional taxes will be due. If we ultimately determine that payment of these amounts is unnecessary, we will reverse the liability and recognize a tax benefit during the period in which we determine that the liability is no longer necessary. We will record an additional charge in our provision for taxes in the period in which we determine that the recorded tax liability is less than we expect the ultimate assessment to be. ASC 740 which requires recognition of estimated income taxes payable or refundable on income tax returns for the current period and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized.

Uncertain Tax Positions When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of FASB ASC 740-10, Accounting for Uncertain Income Tax Positions, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Our federal and state income tax returns are open for fiscal years ending on or after December 31, 2011. We are not under examination by any jurisdiction for any tax year. At June 30, 2016 we had no material unrecognized tax benefits and no adjustments to liabilities or operations were required under FIN 48.

Recent Accounting Pronouncements In September, 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805) ("ASU 2015-16"). Topic 805 requires that an acquirer retrospectively adjust provisional amounts recognized in a business combination, during the measurement period. To simplify the accounting for adjustments made to provisional amounts, the amendments in the Update require that the acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amount is determined. The acquirer is required to also record, in the same period's financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date. In addition an entity is required to present separately on the face of the income statement or disclose in the notes to the financial statements the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date. ASU 2015-16 is effective for fiscal years beginning December 15, 2015. The adoption of ASU 2015-016 is not expected to have a material effect on the Company's consolidated financial statements. In August, 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date ("ASU 2015-14"). The amendment in this ASU defers the effective date of ASU No. 2014-09 for all entities for one year. Public business entities, certain not-for-profit entities, and certain employee benefit plans should apply the guidance in ASU 2014-09 to annual reporting periods beginning December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 31, 2016, including interim reporting periods with that reporting period. In April 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2015-03, Interest-Imputation of Interest (Subtopic 835-30) ("ASU 2015-03"), which changes the presentation of debt issuance costs in financial statements. ASU 2015-03 requires an entity to present such costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. Amortization of the costs will continue to be reported as interest expense. It is effective for annual reporting periods beginning after December 15, 2016. Early adoption is permitted. The new guidance will be applied retrospectively to each prior period presented. The Company is currently in the process of evaluating the impact of adoption of ASU 2015-03 on its balance sheets

Fair Value Measurements at June 30, 2016   <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100.0%;border-collapse:collapse'> <tr align="left"> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Level 3 - Derivative liabilities from: </td> <td valign="bottom" style='padding:0'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Balance at June 30, 2016 </td> <td valign="bottom" style='padding:0'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> New Issuances </td> <td valign="bottom" style='padding:0'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Settlements </td> <td valign="bottom" style='padding:0'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Change in Fair Value </td> </tr> <tr align="left"> <td width="27%" valign="bottom" style='width:27.0%;background:white;padding:0'> Convertible Note </td> <td width="2%" valign="bottom" style='width:2.0%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> $ </td> <td width="16%" valign="bottom" style='width:16.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> - </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> $ </td> <td width="6%" valign="bottom" style='width:6.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> - </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> $ </td> <td width="6%" valign="bottom" style='width:6.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> - </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'>   </td> <td width="9%" valign="bottom" style='width:9.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> - </td> </tr> <tr align="left"> <td width="276" style='border:none'></td> <td width="20" style='border:none'></td> <td width="9" style='border:none'></td> <td width="163" style='border:none'></td> <td width="9" style='border:none'></td> <td width="10" style='border:none'></td> <td width="60" style='border:none'></td> <td width="9" style='border:none'></td> <td width="12" style='border:none'></td> <td width="70" style='border:none'></td> <td width="9" style='border:none'></td> <td width="9" style='border:none'></td> <td width="91" style='border:none'></td> </tr> </table>   Fair Value Measurements at December 31, 2015   <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100.0%;border-collapse:collapse'> <tr align="left"> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Level 3 - Derivative liabilities from: </td> <td valign="bottom" style='padding:0'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Balance at December 31, 2015 </td> <td valign="bottom" style='padding:0'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> New Issuances </td> <td valign="bottom" style='padding:0'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Extinguishment </td> <td valign="bottom" style='padding:0'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Change in Fair Value </td> </tr> <tr align="left"> <td width="27%" valign="bottom" style='width:27.0%;background:white;padding:0'> Convertible Note </td> <td width="2%" valign="bottom" style='width:2.0%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> $ </td> <td width="16%" valign="bottom" style='width:16.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> - </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> $ </td> <td width="6%" valign="bottom" style='width:6.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> - </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> $ </td> <td width="6%" valign="bottom" style='width:6.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> (20,532) </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'>   </td> <td width="9%" valign="bottom" style='width:9.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> - </td> </tr> <tr align="left"> <td width="273" style='border:none'></td> <td width="17" style='border:none'></td> <td width="9" style='border:none'></td> <td width="158" style='border:none'></td> <td width="7" style='border:none'></td> <td width="10" style='border:none'></td> <td width="58" style='border:none'></td> <td width="4" style='border:none'></td> <td width="16" style='border:none'></td> <td width="95" style='border:none'></td> <td width="6" style='border:none'></td> <td width="7" style='border:none'></td> <td width="89" style='border:none'></td> </tr> </table>

Note 8. Derivative Liabilities On July 8, 2014 the company issued a convertible promissory note to Axel Springer Plug & Play Accelerator GmbH (the "Holder"), in the amounts of $29,719. The Convertible note is convertible at the lessor of a market based discounted and a fixed rate derived from a fixed market cap. The Holder has the right following the Date of Issuance, and until any time until the convertible Promissory Note is fully paid, to convert any outstanding and unpaid principal portion of the Convertible Promissory Note, and accrued interest, into fully paid and non-assessable shares of Common Stock. The Holder was not issued warrants with the Convertible Promissory Note. The following shows the changes in the derivative liability measured on a recurring basis for the six months ended June 30, 2016 and year ended December 31, 2015.   <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100.0%;border-collapse:collapse'> <tr style='height:.6pt'> <td valign="bottom" style='padding:0in 0in 1.5pt 0in;height:.6pt'></td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0;height:.6pt'> Level 3 </td> </tr> <tr style='height:.6pt'> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in;height:.6pt'> Derivative Liability at December 31, 2014 </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0;height:.6pt'> $ </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0;height:.6pt'> 20,532 </td> </tr> <tr style='height:.6pt'> <td width="71%" valign="bottom" style='width:71.0%;background:white;padding:0in 0in 1.5pt 0in;height:.6pt'> Extinguishment of Derivative Liability </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0;height:.6pt'></td> <td width="25%" valign="bottom" style='width:25.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0;height:.6pt'> (20,532) </td> </tr> <tr style='height:.6pt'> <td valign="bottom" style='background:white;padding:0;height:.6pt'> Derivative Liability at December 31, 2015 </td> <td valign="bottom" style='background:white;padding:0;height:.6pt'> $ </td> <td valign="bottom" style='background:white;padding:0;height:.6pt'> - </td> </tr> <tr style='height:.6pt'> <td valign="bottom" style='background:white;padding:0in 0in 2.5pt 0in;height:.6pt'> Derivative Liability at June 30, 2016 </td> <td valign="bottom" style='border:none;border-bottom:double black 2.25pt;background:white;padding:0;height:.6pt'> $ </td> <td valign="bottom" style='border:none;border-bottom:double black 2.25pt;background:white;padding:0;height:.6pt'> - </td> </tr> </table>   For the periods ended June 30, 2016 and December 31, 2015 the Company has recognized $0 and $2,013, respectively, in accrued interest expense related to the stated interest rate on the notes. Interest expense for the periods ended June 30, 2016 and December 31, 2015, respectively, were $21,887 and $30,604, of which $0 and $0 is from the amortization of debt discount related to this note The note is no longer considered convertible since the lender elected not to convert, and as such the derivative was written off. As of December 31, 2015 the company has a $0 derivative liability and a $29,719 convertible note payable, net of discount of $0. As of June 30, 2016, the Company has $0 derivative liability and $222,377 of convertible notes payable, net of discount of $412,628. In accordance to ASC #815, Accounting for Derivative Instruments and Hedging Activities, we evaluated the holder's non-detachable conversion right provision and liquidated damages clause, contained in the terms governing the Note to determine whether the features qualify as an embedded derivative instruments at issuance. Such non-detachable conversion right provision and liquidated damages clause did not need to be accounted for as derivative financial instruments. Additionally, since the conversion price of the two notes represented the fair market value of the Company's common stock at the time of issuance, no beneficial conversion feature exists. We believe that the Company's shares of common stock is and have been very thinly traded during the last 3 years and that the fair value of the stock price was deemed not to be a fair value. Management decided that because the Company's ability to continue as a going concern was in question and that it has no revenue sources that the conversion price was a better measure of fair market value. Based on that decision, no beneficial conversion feature was reflected in the financial statements and the $20,165 extinguishment of debt was reflected in the current period earnings and $0 extinguishment of debt was reflected in the current period earnings.

<table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100.0%;border-collapse:collapse'> <tr style='height:.6pt'> <td valign="bottom" style='padding:0in 0in 1.5pt 0in;height:.6pt'></td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0;height:.6pt'> Level 3 </td> </tr> <tr style='height:.6pt'> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in;height:.6pt'> Derivative Liability at December 31, 2014 </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0;height:.6pt'> $ </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0;height:.6pt'> 20,532 </td> </tr> <tr style='height:.6pt'> <td width="71%" valign="bottom" style='width:71.0%;background:white;padding:0in 0in 1.5pt 0in;height:.6pt'> Extinguishment of Derivative Liability </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0;height:.6pt'></td> <td width="25%" valign="bottom" style='width:25.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0;height:.6pt'> (20,532) </td> </tr> <tr style='height:.6pt'> <td valign="bottom" style='background:white;padding:0;height:.6pt'> Derivative Liability at December 31, 2015 </td> <td valign="bottom" style='background:white;padding:0;height:.6pt'> $ </td> <td valign="bottom" style='background:white;padding:0;height:.6pt'> - </td> </tr> <tr style='height:.6pt'> <td valign="bottom" style='background:white;padding:0in 0in 2.5pt 0in;height:.6pt'> Derivative Liability at June 30, 2016 </td> <td valign="bottom" style='border:none;border-bottom:double black 2.25pt;background:white;padding:0;height:.6pt'> $ </td> <td valign="bottom" style='border:none;border-bottom:double black 2.25pt;background:white;padding:0;height:.6pt'> - </td> </tr> </table>

10-Q 2016-06-30 false Emerald Medical Applications Corp. 0000797542 mrla --12-31 19474461 14673348 Smaller Reporting Company Yes No No 2016 Q2

Note 11. Subsequent Events On August 4, 2016, 31,250 shares were issued to one service provider as per the terms of the service agreement. On July 7, 2016, Emerald entered in a Securities Purchase Agreement and a Registration Rights Agreement with Firstfire Global Opportunities Fund LLC, a New York limited liability company (hereinafter "Firstfire"), pursuant to which the Registrant has issued and sold to Firstfire a secured convertible note bearing interest at 8% per annum in the principal amount of $100,000 with a maturity date on June 19, 2017 (the "Note"). In connection with the Securities Purchase Agreement, the Registrant also granted Firstfire 250,000 Class A and 250,000 Class B Warrants.

0000797542 2016-06-30 0000797542 2201-06-30 0000797542 2016-01-01 2016-06-30 0000797542 2015-12-30 0000797542 2016-04-01 2016-06-30 0000797542 2015-04-01 2015-06-30 0000797542 2015-01-01 2015-06-30 0000797542 2015-01-04 2015-06-30 0000797542 2015-12-31 0000797542 2014-12-31 0000797542 2015-06-30 pure iso4217:USD shares iso4217:USD shares $0.0001 par value; 10,000,000 shares authorized; none issued. $0.0001 par value; 490,000,000 shares authorized; 19,474,461 and 15,325,889 issued and outstanding at June 30, 2016 and December 31, 2015, respectively. EX-101.SCH 7 mrla-20160630.xsd 000190 - Disclosure - Note 1. The Company: Other Receivables (Policies) link:presentationLink link:definitionLink link:calculationLink 000070 - Disclosure - Note 2. Stockholders' Equity. link:presentationLink link:definitionLink link:calculationLink 000200 - Disclosure - Note 1. The Company: Currency Translation and Other Comprehensive Income (Policies) link:presentationLink link:definitionLink link:calculationLink 000040 - Statement - Emerald Medical Applications Corp. - Statement of Comprehensive Income (Loss) link:presentationLink link:definitionLink link:calculationLink 000110 - Disclosure - Note 6. Payable - Not Convertible link:presentationLink link:definitionLink link:calculationLink 000210 - Disclosure - Note 1. The Company: Property and Equipment (Policies) link:presentationLink link:definitionLink link:calculationLink 000170 - Disclosure - Note 1. The Company: Use of Estimates (Policies) link:presentationLink link:definitionLink link:calculationLink 000300 - Disclosure - Note 1. The Company: Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Tables) link:presentationLink link:definitionLink link:calculationLink 000160 - Disclosure - Note 11. Subsequent Events link:presentationLink link:definitionLink link:calculationLink 000090 - Disclosure - Note 4. Employee Payable. link:presentationLink link:definitionLink link:calculationLink 000080 - Disclosure - Note 3. Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 000230 - Disclosure - Note 1. The Company: Stock Based Compensation (Policies) link:presentationLink link:definitionLink link:calculationLink 000060 - Disclosure - Note 1. The Company link:presentationLink link:definitionLink link:calculationLink 000020 - Statement - Emerald Medical Applications Corp. - Balance Sheets link:presentationLink link:definitionLink link:calculationLink 000270 - Disclosure - Note 1. The Company: Income Taxes (Policies) link:presentationLink link:definitionLink link:calculationLink 000240 - Disclosure - Note 1. The Company: Accounting For Obligations and Instruments Potentially To Be Settled in The Company's Own Stock (Policies) link:presentationLink link:definitionLink link:calculationLink 000320 - Disclosure - Note 8. Derivative Liabilities: Schedule of Derivative Instruments (Tables) link:presentationLink link:definitionLink link:calculationLink 000030 - Statement - Emerald Medical Applications Corp. - Statements of Operations link:presentationLink link:definitionLink link:calculationLink 000150 - Disclosure - Note 10. Accounts Payable and Accrued Liabilities link:presentationLink link:definitionLink link:calculationLink 000130 - Disclosure - Note 8. Derivative Liabilities link:presentationLink link:definitionLink link:calculationLink 000280 - Disclosure - Note 1. The Company: Uncertain Tax Positions (Policies) link:presentationLink link:definitionLink link:calculationLink 000010 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 000050 - Statement - Emerald Medical Applications Corp. - Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 000140 - Disclosure - Note 9. Other Receivables link:presentationLink link:definitionLink link:calculationLink 000180 - Disclosure - Note 1. The Company: Cash and Cash Equivalents (Policies) link:presentationLink link:definitionLink link:calculationLink 000100 - Disclosure - Note 5. Notes Payable. link:presentationLink link:definitionLink link:calculationLink 000120 - Disclosure - Note 7. Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 000290 - Disclosure - Note 1. The Company: Recent Accounting Pronouncements (Policies) link:presentationLink link:definitionLink link:calculationLink 000260 - Disclosure - Note 1. The Company: Earnings Per Common Share (Policies) link:presentationLink link:definitionLink link:calculationLink 000310 - Disclosure - Note 1. The Company: Fair Value Measurements: Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Tables) link:presentationLink link:definitionLink link:calculationLink 000250 - Disclosure - Note 1. The Company: Fair Value Measurements (Policies) link:presentationLink link:definitionLink link:calculationLink 000220 - Disclosure - Note 1. The Company: Valuation of Long-lived Assets (Policies) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 mrla-20160630_cal.xml EX-101.DEF 9 mrla-20160630_def.xml EX-101.LAB 10 mrla-20160630_lab.xml Valuation of Long-lived Assets Currency Translation and Other Comprehensive Income Note 8. Derivative Liabilities Weighted average shares outstanding Basic and diluted net loss per share Convertible note payable - default Represents the Convertible note payable - default, as of the indicated date. Current Fiscal Year End Date Fair Value Measurements Note 11. Subsequent Events Options issued for services Represents the Options issued for services, during the indicated time period. Shares issued for services Represents the Shares issued for services, during the indicated time period. Liabilities and Stockholders' Equity (Deficit) Fixed assets, net of accumulated depreciation of $10,751 and $6,536, respectively Entity Public Float Trading Symbol Document and Entity Information: Earnings Per Common Share (Decrease) increase in accounts payable - related party Represents the (Decrease) increase in accounts payable - related party, during the indicated time period. Depreciation expense {1} Depreciation expense Represents the Depreciation expense, during the indicated time period. Additional paid in capital Other receivable Balance Sheets Document Fiscal Period Focus Entity Voluntary Filers Schedule of Derivative Instruments in Statement of Financial Position, Fair Value Notes Amortization of debt discount Represents the Amortization of debt discount, during the indicated time period. (Loss) from operations Represents the (Loss) from operations, during the indicated time period. Stockholders' deficit: Entity Current Reporting Status Other Receivables {1} Other Receivables Cash and cash equivalents - beginning of period Cash and cash equivalents - beginning of period Represents the Cash and cash equivalents - beginning of period, as of the indicated date. (Decrease) increase in in other current liabilities Increase (decrease) in cash resulting from changes in: Total comprehensive gain (loss) Statement of Comprehensive Income Depreciation expense Interest expense Common stock Employee payable - related party Represents the Employee payable - related party, as of the indicated date. Entity Well-known Seasoned Issuer Document Type Recent Accounting Pronouncements Property and Equipment Policies BCF due to convertible note payable Represents the BCF due to convertible note payable, during the indicated time period. Cash provided by financing activities Net cash provided by investing activities Decrease (increase) in other receivable Represents the Decrease (increase) in other receivable, during the indicated time period. Expenses: Entity Registrant Name Note 7. Commitments and Contingencies Cashless conversion of class B warrants Represents the Cashless conversion of class B warrants, during the indicated time period. (Decrease) increase in accrued epenses Represents the (Decrease) increase in accrued epenses, during the indicated time period. (Decrease) increase in accounts payable Short term notes payable Represents the Short term notes payable, as of the indicated date. Current liabilities: Document Period End Date Uncertain Tax Positions Use of Estimates Net increase (decrease) in cash Represents the Net increase (decrease) in cash, during the indicated time period. Gain/loss from foreign currency Represents the Gain/loss from foreign currency, during the indicated time period. Current assets: Entity Filer Category Stock Based Compensation Change in fair value of derivative {1} Change in fair value of derivative Represents the Change in fair value of derivative, during the indicated time period. Change in unrealized foreign currency translation gain (loss) Represents the Change in unrealized foreign currency translation gain (loss), during the indicated time period. Basic and diluted Net (loss) Total income (expense) Represents the Total income (expense), during the indicated time period. Other income (expense): Cash and cash equivalents Note 10. Accounts Payable and Accrued Liabilities Principal payments on debt Represents the Principal payments on debt, during the indicated time period. Cash flows from investing activities: Amortizatio expense Change in fair value of derivative Accumulated deficit Convertible note payable - net of discount of $73,562 and $0, respectively Represents the Convertible note payable - net of discount of $73,562 and $0, respectively, as of the indicated date. Document Fiscal Year Focus Tables/Schedules Note 9. Other Receivables Note 6. Payable - Not Convertible Foreign currency adjustments Represents the Foreign currency adjustments, during the indicated time period. Provision for income taxes Represents the Provision for income taxes, during the indicated time period. Research and development Revenue Total Stockholders' equity (deficit) Preferred stock Total current assets Entity Central Index Key Note 5. Notes Payable. Note 3. Related Party Transactions Cash flows from financing activities: Net loss {1} Net loss Represents the Net loss, during the indicated time period. Statements of Cash Flows Accrued interest payable Employee payable Represents the Employee payable, as of the indicated date. Income Taxes Note 4. Employee Payable. (Decrease) increase in employee payable Represents the (Decrease) increase in employee payable, during the indicated time period. Financial income (expense) Represents the Financial income (expense), during the indicated time period. Total operating expenses General and administrative expenses Accounts payable and accrued liabilities Total assets Entity Common Stock, Shares Outstanding Note 2. Stockholders' Equity. Cash paid for fixed assets Represents the Cash paid for fixed assets, during the indicated time period. Net loss Represents the Net loss, during the indicated time period. Schedule of Derivative Instruments Cash flows used by operating activities Represents the Cash flows used by operating activities, during the indicated time period. Due from related party Represents the Due from related party, during the indicated time period. Cash flows from operating activities: Statements of Operations Total Liabilities and Stockholders' Equity Total Liabilities and Stockholders' Equity Total liabilities Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis Cash and Cash Equivalents Non-cash transaction: Cash and cash equivalents - end of period Cash and cash equivalents - end of period Represents the Cash and cash equivalents - end of period, as of the indicated date. Accumulated other comprehensive income (loss) Represents the Accumulated other comprehensive income (loss), as of the indicated date. Total current liabilities Represents the Total current liabilities, as of the indicated date. Amendment Flag Accounting For Obligations and Instruments Potentially To Be Settled in The Company's Own Stock: Note 1. The Company Borrowings on debt Represents the Borrowings on debt, during the indicated time period. Adjustments to reconcile net loss to net cash used in operating activities: Fixed assets, net: Assets {1} Assets EX-101.PRE 11 mrla-20160630_pre.xml XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - USD ($)	6 Months Ended
Document and Entity Information - USD ($)	Jun. 30, 2016	Jun. 30, 2201
Document and Entity Information:
Entity Registrant Name	Emerald Medical Applications Corp.
Document Type	10-Q
Document Period End Date	Jun. 30, 2016
Trading Symbol	mrla
Amendment Flag	false
Entity Central Index Key	0000797542
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding	19,474,461
Entity Public Float		$ 14,673,348
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q2

XML 13 R2.htm IDEA: XBRL DOCUMENT

Emerald Medical Applications Corp. - Balance Sheets

Jun. 30, 2016

USD ($)

Dec. 30, 2015

USD ($)

Current assets:

Cash and cash equivalents

$ 274,759

$ 115,449

Other receivable

8,212

25,797

Total current assets

282,971

141,246

Fixed assets, net:

Fixed assets, net of accumulated depreciation of $10,751 and $6,536, respectively

17,735

21,120

Total assets

300,706

162,366

Current liabilities:

Accounts payable and accrued liabilities

$ 48,204

$ 90,705

Employee payable

22,786

25,612

Employee payable - related party

3,081

3,480

Accrued interest payable

$ 21,887

$ 19,285

Short term notes payable

186,336

119,974

Convertible note payable - default

29,719

Convertible note payable - net of discount of $73,562 and $0, respectively

222,377

29,719

Total current liabilities

534,390

288,775

Total liabilities

$ 534,390

$ 288,775

Stockholders' deficit:

Preferred stock

^[1]

Common stock

^[2]

$ 1,948

$ 1,533

Accumulated other comprehensive income (loss)

(24,178)

(19,337)

Additional paid in capital

$ 11,738,066

$ 8,752,711

Accumulated deficit

(11,949,520)

(8,861,316)

Total Stockholders' equity (deficit)

(233,684)

(126,409)

Total Liabilities and Stockholders' Equity

$ 300,706

$ 162,366

[1]	$0.0001 par value; 10,000,000 shares authorized; none issued.
[2]	$0.0001 par value; 490,000,000 shares authorized; 19,474,461 and 15,325,889 issued and outstanding at June 30, 2016 and December 31, 2015, respectively.

XML 14 R3.htm IDEA: XBRL DOCUMENT

Emerald Medical Applications Corp. - Statements of Operations	3 Months Ended		6 Months Ended
	Jun. 30, 2016 USD ($) $ / shares shares	Jun. 30, 2015 USD ($) $ / shares shares	Jun. 30, 2016 USD ($) $ / shares shares	Jun. 30, 2015 USD ($) $ / shares shares
Statements of Operations
Revenue	$ 0	$ 0	$ 0	$ 0
Expenses:
Research and development	(192,002)	(237,095)	(295,350)	(247,400)
General and administrative expenses	(969,216)	(5,570)	(2,768,736)	(174,391)
Total operating expenses	$ (1,161,218)	$ (242,665)	$ (3,064,086)	$ (421,791)
(Loss) from operations	(1,161,218)	(242,665)	(3,064,086)	(421,791)
Other income (expense):
Interest expense	$ (14,128)	$ (4,346)	$ (21,887)	$ (11,829)
Change in fair value of derivative	0	0	0	367
Depreciation expense	(47,718)	0	(51,665)	0
Amortizatio expense	$ 28,587	$ 0	$ 28,587	$ 0
Gain/loss from foreign currency	6,503	(4,110)	20,847	1,808
Financial income (expense)	(26,756)	(8,456)	(24,118)	(9,654)
Total income (expense)	(1,187,974)	(251,121)	(3,088,204)	(431,445)
Provision for income taxes	0	0	0	0
Net (loss)	$ (1,187,974)	$ (251,121)	$ (3,088,204)	$ (431,445)
Basic and diluted net loss per share \| $ / shares	$ (0.06)	$ (1.18)	$ (0.17)	$ (2.03)
Weighted average shares outstanding
Basic and diluted \| shares	18,890,670	213,001	18,121,314	213,001

XML 15 R4.htm IDEA: XBRL DOCUMENT

Emerald Medical Applications Corp. - Statement of Comprehensive Income (Loss)	3 Months Ended	6 Months Ended
	Jun. 30, 2016 USD ($)	Jun. 30, 2016 USD ($)	Jun. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)
Statement of Comprehensive Income
Net loss	(1,187,974)	(3,088,204)	(251,121)	(431,445)
Change in unrealized foreign currency translation gain (loss)	(3)	(4,841)	(15,771)	(25,550)
Total comprehensive gain (loss)	$ (1,187,977)	$ (3,093,045)	$ (266,892)	$ (456,995)

XML 16 R5.htm IDEA: XBRL DOCUMENT

Emerald Medical Applications Corp. - Statements of Cash Flows	6 Months Ended
	Jun. 30, 2016 USD ($)	Jun. 30, 2015 USD ($)
Cash flows from operating activities:
Net loss	(3,088,204)	(431,445)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	8,293	1,878
Amortization of debt discount	43,373	4,399
Change in fair value of derivative	0	(367)
Shares issued for services	2,074,736	0
Options issued for services	455,032	0
Increase (decrease) in cash resulting from changes in:
Due from related party	0	(6,443)
Decrease (increase) in other receivable	17,585	(25,689)
(Decrease) increase in accounts payable	$ (1,777)	$ (2,577)
(Decrease) increase in accounts payable - related party	0	1,087
(Decrease) increase in employee payable	0	23,800
(Decrease) increase in in other current liabilities	$ 0	$ 14,202
(Decrease) increase in accrued epenses	(45,779)	7,430
Cash flows used by operating activities	(536,741)	(413,725)
Cash flows from investing activities:
Cash paid for fixed assets	(474)	25,317
Net cash provided by investing activities	$ (474)	$ 25,317
Cash flows from financing activities:
Borrowings on debt	735,913	531,798
Principal payments on debt	(34,547)	0
Cash provided by financing activities	$ 701,366	$ 531,798
Foreign currency adjustments	(4,841)	(25,550)
Net increase (decrease) in cash	159,310	67,206
Cash and cash equivalents - beginning of period	115,449	14,411
Cash and cash equivalents - end of period	274,759	56,067
Non-cash transaction:
BCF due to convertible note payable	456,000	0
Cashless conversion of class B warrants	193	0

XML 17 R6.htm IDEA: XBRL DOCUMENT

Note 1. The Company

6 Months Ended

Jun. 30, 2016

Notes

Note 1. The Company

Note 1. The Company

Organizational Background

Basis of Presentation

The Company elected December 31 as its fiscal year end.

Significant Accounting Policies

Use of Estimates

Cash and Cash Equivalents

Other Receivables

The company treats VAT refunds claimed resulting from excess VAT paid over VAT received as other receivables, amount shown as other receivables as of June 30, 2016 was $8,212.

Currency Translation and other Comprehensive Income

Property and Equipment

ce.

Valuation of Long-Lived Assets

Stock Based Compensation

Accounting For Obligations And Instruments Potentially To Be Settled In The Company's Own Stock:

Fair Value Measurements

As a basis for considering such assumptions, the standard established a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows.

Level 1. Observable inputs such as quoted prices in active markets; Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

Fair Value Measurements at June 30, 2016

Level 3 - Derivative liabilities from:

Balance at June 30, 2016

New Issuances

Settlements

Change in Fair Value

Convertible Note

Fair Value Measurements at December 31, 2015

Level 3 - Derivative liabilities from:	Balance at December 31, 2015		New Issuances		Extinguishment		Change in Fair Value
Convertible Note	$	-	$	-	$	(20,532)		-

The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of June 30, 2016 and December 31, 2015:

Fair Value Measurements at June 30, 2016

	Level 3
Assets
Total Assets	$	-

Liabilities
Derivative liability	$	-
Total Liabilities	$	-

Fair Value Measurements at December 31, 2015

		Level 3
Assets
Total Assets	$	-

Liabilities
Derivative liability	$	-
Total Liabilities	$	-

The fair values of our debts are deemed to approximate book value, and are considered Level 2 inputs as defined by ASC Topic 820-10-35.

There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the six months ended June 30, 2016 or the year ended December 31, 2015.

The Company had no other assets or liabilities valued at fair value on a recurring or non-recurring basis as of June 30, 2016 or December 31, 2015.

Earnings per Common Share

Income Taxes

Uncertain Tax Positions

Recent Accounting Pronouncements

Going Concern

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. The Company has not established any source of revenue to cover its operating costs, and as such, has incurred an operating loss since inception. Further, as of June 30, 2016, the cash resources of the Company were insufficient to meet its current business plan, and the Company had negative working capital. These and other factors raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

XML 18 R7.htm IDEA: XBRL DOCUMENT

Note 2. Stockholders' Equity.

6 Months Ended

Jun. 30, 2016

Notes

Note 2. Stockholders' Equity.

Note 2. Stockholders' Equity.

Recent Issuances of Common Stock

On July 16, 2015 consultants were issued 2,500,000 Class B Warrants exercisable for a two-year period to acquire one (1) share of Common Stock at a price of $0.40 per share The fair value of these warrants is $2,199,507. The warrants were valued using the Black-Scholes model with volatility of 182% and discount rate of 0.67%. The Class B warrants are fully vested and were accordingly included in expenses as stock based compensation.

On April 5, 2016, the Company issued 150,000 shares to one service provider for services valued at $105,000 based on the Company's stock price of $0.70 per share on the date of issuance.

On May 10, 2016, the Company issued 41,667 shares to one service provider for services valued at $72,911 based on the Company's stock price of $1.75 per share on the date of issuance.

On May 18, 2016, the Company issued 150,000 shares to one service provider for services valued at $102,000 based on the Company's stock price of $0.68 per share on the date of issuance.

On June 28, 2016, the Company issued 175,000 shares to one service provider for services valued at $122,500 based on the Company's stock price of $0.70 per share on the date of issuance.

On June 30, 2016, the Company issued 333,333 shares to one service provider for services valued at $226,666 based on the Company's stock price of $0.68 per share on the date of issuance.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

XML 19 R8.htm IDEA: XBRL DOCUMENT

Note 3. Related Party Transactions

6 Months Ended

Jun. 30, 2016

Notes

Note 3. Related Party Transactions

Note 3. Related Party Transactions

The company's CEO, Lior Wayn was owed $3,310 and $3,480 payable as of June 30, 2016 and December 31, 2015, respectively.

Following Closing of the reverse merger, $490,000 loan from Zaxis International Inc. to Emerald Medical Applications Ltd. was rendered an intercompany loan and as such was written off.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

XML 20 R9.htm IDEA: XBRL DOCUMENT

Note 4. Employee Payable.

6 Months Ended

Jun. 30, 2016

Notes

Note 4. Employee Payable.

Note 4. Employee Payable.

For the periods ended June 30, 2016 and December 31, 2015 the Company had $25,867 and $25,612, respectively, in employee payable related to the monthly wages payable to the company's employees.

XML 21 R10.htm IDEA: XBRL DOCUMENT

Note 5. Notes Payable.

6 Months Ended

Jun. 30, 2016

Notes

Note 5. Notes Payable.

Note 5. Notes Payable.

Convertible Notes Payable

XML 22 R11.htm IDEA: XBRL DOCUMENT

Note 6. Payable - Not Convertible

6 Months Ended

Jun. 30, 2016

Notes

Note 6. Payable - Not Convertible

Note 6. Payable - Not Convertible

One of the notes was repaid in full on March 3, 2015 with interest due waived the by the debtor, and the second note was repaid on April 22, 2015 with interest due waived the by the debtor.

XML 23 R12.htm IDEA: XBRL DOCUMENT

Note 7. Commitments and Contingencies

6 Months Ended

Jun. 30, 2016

Notes

Note 7. Commitments and Contingencies

Note 7. Commitments and Contingencies

XML 24 R13.htm IDEA: XBRL DOCUMENT

Note 8. Derivative Liabilities

6 Months Ended

Jun. 30, 2016

Notes

Note 8. Derivative Liabilities

Note 8. Derivative Liabilities

On July 8, 2014 the company issued a convertible promissory note to Axel Springer Plug & Play Accelerator GmbH (the "Holder"), in the amounts of $29,719.

The following shows the changes in the derivative liability measured on a recurring basis for the six months ended June 30, 2016 and year ended December 31, 2015.

	Level 3
Derivative Liability at December 31, 2014	$	20,532
Extinguishment of Derivative Liability		(20,532)
Derivative Liability at December 31, 2015	$	-
Derivative Liability at June 30, 2016	$	-

XML 25 R14.htm IDEA: XBRL DOCUMENT

Note 9. Other Receivables

6 Months Ended

Jun. 30, 2016

Notes

Note 9. Other Receivables

Note 9. Other Receivables

As of June 30, 2016 and December 31, 2015 the Company had other receivables of $8,212 and $25,797, respectively, which represent VAT refunds claimed resulting from excess VAT paid over VAT received.

XML 26 R15.htm IDEA: XBRL DOCUMENT

Note 10. Accounts Payable and Accrued Liabilities

6 Months Ended

Jun. 30, 2016

Notes

Note 10. Accounts Payable and Accrued Liabilities

Note 10. Accounts Payable and Accrued Liabilities

As of June 30, 2016 and December 31, 2015, the Company had Accounts payable and accrued liabilities of $48,204 and $90,705, respectively.

XML 27 R16.htm IDEA: XBRL DOCUMENT

Note 11. Subsequent Events

6 Months Ended

Jun. 30, 2016

Notes

Note 11. Subsequent Events

Note 11. Subsequent Events

On August 4, 2016, 31,250 shares were issued to one service provider as per the terms of the service agreement.

XML 28 R17.htm IDEA: XBRL DOCUMENT

Note 1. The Company: Use of Estimates (Policies)

6 Months Ended

Jun. 30, 2016

Policies

Use of Estimates

Use of Estimates

XML 29 R18.htm IDEA: XBRL DOCUMENT

Note 1. The Company: Cash and Cash Equivalents (Policies)

6 Months Ended

Jun. 30, 2016

Policies

Cash and Cash Equivalents

Cash and Cash Equivalents

- Definition

Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.

+ References + Details

XML 30 R19.htm IDEA: XBRL DOCUMENT

Note 1. The Company: Other Receivables (Policies)

6 Months Ended

Jun. 30, 2016

Policies

Other Receivables

Other Receivables

The company treats VAT refunds claimed resulting from excess VAT paid over VAT received as other receivables, amount shown as other receivables as of June 30, 2016 was $8,212.

- Definition

Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables. If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.

+ References + Details

XML 31 R20.htm IDEA: XBRL DOCUMENT

Note 1. The Company: Currency Translation and Other Comprehensive Income (Policies)

6 Months Ended

Jun. 30, 2016

Policies

Currency Translation and Other Comprehensive Income

Currency Translation and other Comprehensive Income

XML 32 R21.htm IDEA: XBRL DOCUMENT

Note 1. The Company: Property and Equipment (Policies)

6 Months Ended

Jun. 30, 2016

Policies

Property and Equipment

Property and Equipment

XML 33 R22.htm IDEA: XBRL DOCUMENT

Note 1. The Company: Valuation of Long-lived Assets (Policies)

6 Months Ended

Jun. 30, 2016

Policies

Valuation of Long-lived Assets

Valuation of Long-Lived Assets

XML 34 R23.htm IDEA: XBRL DOCUMENT

Note 1. The Company: Stock Based Compensation (Policies)

6 Months Ended

Jun. 30, 2016

Policies

Stock Based Compensation

Stock Based Compensation

XML 35 R24.htm IDEA: XBRL DOCUMENT

Note 1. The Company: Accounting For Obligations and Instruments Potentially To Be Settled in The Company's Own Stock (Policies)

6 Months Ended

Jun. 30, 2016

Policies

Accounting For Obligations and Instruments Potentially To Be Settled in The Company's Own Stock:

Accounting For Obligations And Instruments Potentially To Be Settled In The Company's Own Stock:

XML 36 R25.htm IDEA: XBRL DOCUMENT

Note 1. The Company: Fair Value Measurements (Policies)

6 Months Ended

Jun. 30, 2016

Policies

Fair Value Measurements

Fair Value Measurements

As a basis for considering such assumptions, the standard established a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows.

Level 1. Observable inputs such as quoted prices in active markets; Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

Fair Value Measurements at June 30, 2016

Level 3 - Derivative liabilities from:

Balance at June 30, 2016

New Issuances

Settlements

Change in Fair Value

Convertible Note

Fair Value Measurements at December 31, 2015

Level 3 - Derivative liabilities from:	Balance at December 31, 2015		New Issuances		Extinguishment		Change in Fair Value
Convertible Note	$	-	$	-	$	(20,532)		-

The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of June 30, 2016 and December 31, 2015:

Fair Value Measurements at June 30, 2016

	Level 3
Assets
Total Assets	$	-

Liabilities
Derivative liability	$	-
Total Liabilities	$	-

Fair Value Measurements at December 31, 2015

		Level 3
Assets
Total Assets	$	-

Liabilities
Derivative liability	$	-
Total Liabilities	$	-

The fair values of our debts are deemed to approximate book value, and are considered Level 2 inputs as defined by ASC Topic 820-10-35.

There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the six months ended June 30, 2016 or the year ended December 31, 2015.

The Company had no other assets or liabilities valued at fair value on a recurring or non-recurring basis as of June 30, 2016 or December 31, 2015.

XML 37 R26.htm IDEA: XBRL DOCUMENT

Note 1. The Company: Earnings Per Common Share (Policies)

6 Months Ended

Jun. 30, 2016

Policies

Earnings Per Common Share

Earnings per Common Share

XML 38 R27.htm IDEA: XBRL DOCUMENT

Note 1. The Company: Income Taxes (Policies)

6 Months Ended

Jun. 30, 2016

Policies

Income Taxes

Income Taxes

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References + Details

XML 39 R28.htm IDEA: XBRL DOCUMENT

Note 1. The Company: Uncertain Tax Positions (Policies)

6 Months Ended

Jun. 30, 2016

Policies

Uncertain Tax Positions

Uncertain Tax Positions

XML 40 R29.htm IDEA: XBRL DOCUMENT

Note 1. The Company: Recent Accounting Pronouncements (Policies)

6 Months Ended

Jun. 30, 2016

Policies

Recent Accounting Pronouncements

Recent Accounting Pronouncements

XML 41 R30.htm IDEA: XBRL DOCUMENT

Note 1. The Company: Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Tables)

6 Months Ended

Jun. 30, 2016

Tables/Schedules

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

Fair Value Measurements at June 30, 2016

Level 3 - Derivative liabilities from:

Balance at June 30, 2016

New Issuances

Settlements

Change in Fair Value

Convertible Note

Fair Value Measurements at December 31, 2015

Level 3 - Derivative liabilities from:	Balance at December 31, 2015		New Issuances		Extinguishment		Change in Fair Value
Convertible Note	$	-	$	-	$	(20,532)		-

XML 42 R31.htm IDEA: XBRL DOCUMENT

Note 1. The Company: Fair Value Measurements: Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Tables)

6 Months Ended

Jun. 30, 2016

Tables/Schedules

Schedule of Derivative Instruments in Statement of Financial Position, Fair Value

	Level 3
Assets
Total Assets	$	-

Liabilities
Derivative liability	$	-
Total Liabilities	$	-

Fair Value Measurements at December 31, 2015

		Level 3
Assets
Total Assets	$	-

Liabilities
Derivative liability	$	-
Total Liabilities	$	-

XML 43 R32.htm IDEA: XBRL DOCUMENT

Note 8. Derivative Liabilities: Schedule of Derivative Instruments (Tables)

6 Months Ended

Jun. 30, 2016

Tables/Schedules

Schedule of Derivative Instruments

	Level 3
Derivative Liability at December 31, 2014	$	20,532
Extinguishment of Derivative Liability		(20,532)
Derivative Liability at December 31, 2015	$	-
Derivative Liability at June 30, 2016	$	-

- Definition

Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41641-113959

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624163-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41678-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41638-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5580258-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5579245-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624171-113959

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5579240-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41620-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

EXCEL 44 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 45 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 46 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 48 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 11 107 1 true 0 0 false 4 false false R1.htm 000010 - Document - Document and Entity Information Sheet http://dermacompare.com/20160630/role/idr_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 000020 - Statement - Emerald Medical Applications Corp. - Balance Sheets Sheet http://dermacompare.com/20160630/role/idr_EmeraldMedicalApplicationsCorpBalanceSheets Emerald Medical Applications Corp. - Balance Sheets Statements 2 false false R3.htm 000030 - Statement - Emerald Medical Applications Corp. - Statements of Operations Sheet http://dermacompare.com/20160630/role/idr_EmeraldMedicalApplicationsCorpStatementsOfOperations Emerald Medical Applications Corp. - Statements of Operations Statements 3 false false R4.htm 000040 - Statement - Emerald Medical Applications Corp. - Statement of Comprehensive Income (Loss) Sheet http://dermacompare.com/20160630/role/idr_EmeraldMedicalApplicationsCorpStatementOfComprehensiveIncomeLoss Emerald Medical Applications Corp. - Statement of Comprehensive Income (Loss) Statements 4 false false R5.htm 000050 - Statement - Emerald Medical Applications Corp. - Statements of Cash Flows Sheet http://dermacompare.com/20160630/role/idr_EmeraldMedicalApplicationsCorpStatementsOfCashFlows Emerald Medical Applications Corp. - Statements of Cash Flows Statements 5 false false R6.htm 000060 - Disclosure - Note 1. The Company Sheet http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompany Note 1. The Company Notes 6 false false R7.htm 000070 - Disclosure - Note 2. Stockholders' Equity. Sheet http://dermacompare.com/20160630/role/idr_DisclosureNote2StockholdersEquity Note 2. Stockholders' Equity. Notes 7 false false R8.htm 000080 - Disclosure - Note 3. Related Party Transactions Sheet http://dermacompare.com/20160630/role/idr_DisclosureNote3RelatedPartyTransactions Note 3. Related Party Transactions Notes 8 false false R9.htm 000090 - Disclosure - Note 4. Employee Payable. Sheet http://dermacompare.com/20160630/role/idr_DisclosureNote4EmployeePayable Note 4. Employee Payable. Notes 9 false false R10.htm 000100 - Disclosure - Note 5. Notes Payable. Notes http://dermacompare.com/20160630/role/idr_DisclosureNote5NotesPayable Note 5. Notes Payable. Notes 10 false false R11.htm 000110 - Disclosure - Note 6. Payable - Not Convertible Sheet http://dermacompare.com/20160630/role/idr_DisclosureNote6PayableNotConvertible Note 6. Payable - Not Convertible Notes 11 false false R12.htm 000120 - Disclosure - Note 7. Commitments and Contingencies Sheet http://dermacompare.com/20160630/role/idr_DisclosureNote7CommitmentsAndContingencies Note 7. Commitments and Contingencies Notes 12 false false R13.htm 000130 - Disclosure - Note 8. Derivative Liabilities Sheet http://dermacompare.com/20160630/role/idr_DisclosureNote8DerivativeLiabilities Note 8. Derivative Liabilities Notes 13 false false R14.htm 000140 - Disclosure - Note 9. Other Receivables Sheet http://dermacompare.com/20160630/role/idr_DisclosureNote9OtherReceivables Note 9. Other Receivables Notes 14 false false R15.htm 000150 - Disclosure - Note 10. Accounts Payable and Accrued Liabilities Sheet http://dermacompare.com/20160630/role/idr_DisclosureNote10AccountsPayableAndAccruedLiabilities Note 10. Accounts Payable and Accrued Liabilities Notes 15 false false R16.htm 000160 - Disclosure - Note 11. Subsequent Events Sheet http://dermacompare.com/20160630/role/idr_DisclosureNote11SubsequentEvents Note 11. Subsequent Events Notes 16 false false R17.htm 000170 - Disclosure - Note 1. The Company: Use of Estimates (Policies) Sheet http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyUseOfEstimatesPolicies Note 1. The Company: Use of Estimates (Policies) Policies 17 false false R18.htm 000180 - Disclosure - Note 1. The Company: Cash and Cash Equivalents (Policies) Sheet http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyCashAndCashEquivalentsPolicies Note 1. The Company: Cash and Cash Equivalents (Policies) Policies 18 false false R19.htm 000190 - Disclosure - Note 1. The Company: Other Receivables (Policies) Sheet http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyOtherReceivablesPolicies Note 1. The Company: Other Receivables (Policies) Policies 19 false false R20.htm 000200 - Disclosure - Note 1. The Company: Currency Translation and Other Comprehensive Income (Policies) Sheet http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyCurrencyTranslationAndOtherComprehensiveIncomePolicies Note 1. The Company: Currency Translation and Other Comprehensive Income (Policies) Policies 20 false false R21.htm 000210 - Disclosure - Note 1. The Company: Property and Equipment (Policies) Sheet http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyPropertyAndEquipmentPolicies Note 1. The Company: Property and Equipment (Policies) Policies 21 false false R22.htm 000220 - Disclosure - Note 1. The Company: Valuation of Long-lived Assets (Policies) Sheet http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyValuationOfLongLivedAssetsPolicies Note 1. The Company: Valuation of Long-lived Assets (Policies) Policies 22 false false R23.htm 000230 - Disclosure - Note 1. The Company: Stock Based Compensation (Policies) Sheet http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyStockBasedCompensationPolicies Note 1. The Company: Stock Based Compensation (Policies) Policies 23 false false R24.htm 000240 - Disclosure - Note 1. The Company: Accounting For Obligations and Instruments Potentially To Be Settled in The Company's Own Stock (Policies) Sheet http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyAccountingForObligationsAndInstrumentsPotentiallyToBeSettledInTheCompanySOwnStockPolicies Note 1. The Company: Accounting For Obligations and Instruments Potentially To Be Settled in The Company's Own Stock (Policies) Policies 24 false false R25.htm 000250 - Disclosure - Note 1. The Company: Fair Value Measurements (Policies) Sheet http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyFairValueMeasurementsPolicies Note 1. The Company: Fair Value Measurements (Policies) Policies 25 false false R26.htm 000260 - Disclosure - Note 1. The Company: Earnings Per Common Share (Policies) Sheet http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyEarningsPerCommonSharePolicies Note 1. The Company: Earnings Per Common Share (Policies) Policies 26 false false R27.htm 000270 - Disclosure - Note 1. The Company: Income Taxes (Policies) Sheet http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyIncomeTaxesPolicies Note 1. The Company: Income Taxes (Policies) Policies 27 false false R28.htm 000280 - Disclosure - Note 1. The Company: Uncertain Tax Positions (Policies) Sheet http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyUncertainTaxPositionsPolicies Note 1. The Company: Uncertain Tax Positions (Policies) Policies 28 false false R29.htm 000290 - Disclosure - Note 1. The Company: Recent Accounting Pronouncements (Policies) Sheet http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyRecentAccountingPronouncementsPolicies Note 1. The Company: Recent Accounting Pronouncements (Policies) Policies 29 false false R30.htm 000300 - Disclosure - Note 1. The Company: Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Tables) Sheet http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTables Note 1. The Company: Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Tables) Tables 30 false false R31.htm 000310 - Disclosure - Note 1. The Company: Fair Value Measurements: Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Tables) Sheet http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyFairValueMeasurementsScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTables Note 1. The Company: Fair Value Measurements: Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Tables) Tables 31 false false R32.htm 000320 - Disclosure - Note 8. Derivative Liabilities: Schedule of Derivative Instruments (Tables) Sheet http://dermacompare.com/20160630/role/idr_DisclosureNote8DerivativeLiabilitiesScheduleOfDerivativeInstrumentsTables Note 8. Derivative Liabilities: Schedule of Derivative Instruments (Tables) Tables 32 false false All Reports Book All Reports mrla-20160630.xml mrla-20160630.xsd mrla-20160630_cal.xml mrla-20160630_def.xml mrla-20160630_lab.xml mrla-20160630_pre.xml true true ZIP 50 0001295345-16-000646-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001295345-16-000646-xbrl.zip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

Emerald Medical Applications Corp.
Statements of Operations
For the Three and Six Months Ended June 30, 2016 and 2015
(Unaudited)
Back to Table of Contents

		Three months		Three months		Six months		Six months
		ended		ended		ended		ended
		June 30, 2016		June 30, 2015		June 30, 2016		June 30, 2015

Revenues	$	-	$	-	$	-	$	-

Expenses:
Research and development		(192,002)		(237,095)		(295,350)		(247,400)
General and administrative expenses		(969,214)		(5,570)		(2,768,736)		(174,391)
Total operating expenses		(1,161,218)		(242,665)		(3,064,086)		(421,791)

Loss from operations		(1,161,218)		(242,665)		(3,064,086)		(421,791)

Other income (expense):
Interest expense		(14,128)		(4,346)		(21,887)		(11,829)
Change in fair value of derivative		-		-		-		367
Depreciation and amortization expense		(47,718)		-		(51,665)		-
Other income (expenses)		28,587		-		28,587		-
Gain/(loss) from foreign currency		6,503		(4,110)		20,847		1,808
Financial income (expense)		(26,756)		(8,456)		(24,118)		(9,654)

Provision for income taxes		-		-		-		-

Net loss	$	(1,187,974)	$	(251,121)	$	(3,088,204)	$	(431,445)

Basic and diluted (net loss per share)	$	(0.06)	$	(1.18)	$	(0.17)	$	(2.03)
Weighted average shares outstanding - basic and diluted		18,890,670		213,001		18,121,314		213,001

The accompanying notes are an integral part of these financial statements.

Emerald Medical Applications Corp.
Statements of Cash Flows
For the Six Months Ended June 30, 2016 and 2015
(Unaudited)
Back to Table of Contents

	Six months		Six months
	ended		ended
	June 30, 2016		June 30, 2015
Operating Activities:

Net loss	$	(3,088,204)	$	(431,445)
Adjustments to reconcile net (loss) to net cash (used in) operating activities:
Depreciation expense		8,293		1,878
Amortization of debt discount		43,373		4,399
Change in fair value of derivative liabilities		-		(367)
Shares issued for services		2,074,736		-
Options issued for services		455,032		-
Increase (decrease) in cash resulting from change in:
Due from related party		-		(6,443)
Decrease (increase) in other receivable		17,585		(25,689)
(Decrease) increase in accounts payable		(1,777)		(2,577)
(Decrease) increase in accounts payable - related party		-		1,087
Employee payable		-		23,800
(Decrease) increase in other current liabilities		-		14,202
(Decrease) increase in accrued expenses		(45,779)		7,430
Net cash used in operating activities	$	(536,741)	$	(413,725)

Investing Activities:
Cash paid for fixed assets	$	(474)	$	25,317
Net cash provided by investing activities	$	(474)	$	25,317

Financing Activities:
Borrowings on debt	$	735,913	$	531,798
Principal payments on debt		(34,547)		-
Net cash provided by financing activities	$	701,366	$	531,798

Foreign currency adjustment		(4,841)		(25,550)

Net increase (decrease) in cash		159,310		67,206
Cash and cash equivalents - beginning of period		115,449		14,411
Cash and cash equivalents - end of period	$	274,759	$	81,617

Non-cash transactions:
BCF due to convertible note payable	$	456,000	$	-
Cashless conversion of class B warrants	$	193	$	-

The accompanying notes are an integral part of these financial statements.